

May, 2020

Curriculum Vitae - Pinchas Cohen

**Dean, USC Leonard Davis School of Gerontology
Executive Director, Ethel Percy Andrus Gerontology Center
Holder, William & Sylvia Kugel Gerontology Dean's Chair
University of Southern California**

Home Page: <http://gero.usc.edu/faculty/cohen/>

Office Address: 3715 McClintock Avenue, Suite 103, Los Angeles, CA 90089-0191
Tel: 213-740-1354; e-mail: hassy@usc.edu

Citizenship: US citizen (1998)

Military Service: 1975-1978 Israeli Air Force and Medical Corps

Education: 1978-1986 M.D., (with highest honors)
Faculty of Medicine, Technion, Haifa, Israel

Postgraduate Training and Fellowship Appointments:

1986-1989 Intern and Resident, Department of Pediatrics,
Stanford University, Stanford, California

1989-1992 Endocrine/Diabetes Fellow,
Department of Pediatrics, Stanford, California

Faculty Appointments:

1992 Assistant Professor, Department of Pediatrics,
University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania

1997 Associate Professor (*with tenure*),
University of Pennsylvania, School of Medicine

1999 Professor of Pediatrics,
University of California at Los Angeles, School of Medicine

2012 Professor of Gerontology and Medicine
University of Southern California

Administrative Appointments:

1996-1999	Program Director, Pediatric Endocrinology and Diabetes University of Pennsylvania
1999-2012	Director of Endocrine/Diabetes Research and Training Mattel Children's Hospital UCLA
2001-2012	Chief, Division of Endocrinology and Diabetes Mattel Children's Hospital UCLA
2007-2012	Co-Director (2007-2010) and Director (2011-2012) UCSD/UCLA Diabetes/Endocrinology Research Center (DRC)
2011-2012	Training Director, UCLA-CHRCDA-K12 Child Health Research Career Development Award Program
2011-2012	Vice-Chair of Research, Mattel Children's Hospital UCLA
2012-	Dean, USC Davis School of Gerontology
2012-	Executive Director, Ethel Percy Andrus Gerontology Center, USC

Specialty Certification:

1991	Diplomat, American Board of Pediatrics (recertified)
1995	Diplomat, American Board of Pediatric Endocrinology (recertified)

Licensure: Medical License - California and Pennsylvania

Awards, Honors and Membership in Honorary Societies:

1982	The David and Margaret Rue Award for Outstanding Student
1984	The Israeli Diabetes Foundation Young Investigator of the Year
1985	Technion First prize for MD thesis
1986	Graduated from Medical School with highest honors
1989	Juvenile Diabetes Foundation Fellow
1990	Pediatric Endocrine Society Research Fellow (Lilly Award)
1991	WSPR Young Investigator Research Prize (Ross Award)
1992	Child Health Research Center Investigator
1993	American Diabetes Association Career Development Award
1995	Elected member: Society for Pediatric Research
1996	Voted into "The Best Doctors in America"
1997	Masters of Science (Honorary), University of Pennsylvania
1998	Honorary Member: Japanese Society of Pediatric Endocrinology
2000	Pfeiffer Foundation Research Award
2005	Prostate Cancer Foundation (CaP Cure) Research Award
2006	Elected member: American Pediatric Society (APS)
2007	American Pediatric Society Outstanding Science Award
2008	Awarded the NIA-EUREKA Award
2009	Awarded the NIH-Director Transformative RO1 Award
2010	Stanford University Kroc visiting Professorship
2011	Glenn Award for Research in Biological Mechanisms of Aging
2012	William & Sylvia Kugel Gerontology Dean's Chair at USC
2013	Milken Institute Associate
2014	President, The Growth Hormone Research Society
2016	Association of Gerontology Higher Education Administrative Leadership Award
2017	Elected Member, National Academy of Inventors
2017	PBS-Next Avenue Top 50 Influencers in Aging
2018	AFAR BIG AWARD
2018	Schüeler Distinguished Lecture in Pharmacology, Tulane University
2019	Irving S. Wright Award of Distinction - American Federation for Aging Research
2019	Elected: Fellow of the Gerontological Society of America

Advisory Service and Board Membership:

1997-2007	Executive Board Member of the International IGF Society
1997-2001	Member LWPES Program Directors Committee
1998-2018	Executive Council Member: Growth Hormone Research Society
1999-2009	Member: Advisory Board for the University of Washington Cancer Program
2002-2005	Member: Endocrine Society Steering Committee
2002-2006	Member LWPES Drugs and Therapeutics Committee
2006-2009	Member: Advisory Board for the NIA CALERIE study
2009-2012	Member: National Diabetes Centers Directors Executive Committee
2015-2020	Member, Milken Institute Center for the Future of Aging Advisory Board
2015-	Director, CohBar Inc.
2016-2018	Member, Board of Directors of the American Society of Aging

Grant Study Sections

VA Merit Review Study Section Member 1995-9
NIH GCRC study section Ad Hoc Reviewer 1995-7
Doris Duke Foundation Study Section Member 1997-9
Canadian Cancer Society Study Section Member 2000-2
NIDDK Urology Special Emphasis Programs 2003-6
Chair, UCLA/UCSD DERC P&F grant study section 2003-12
NCI Site visit study section member 2004
NIA Proteomics and Aging RFA Study Section 2004
NCI Oncology Cell Tissue Biology PO1 Study Section 2005-9
NCI Tumor Cell Biology Study Section 2006-8
NIDDK GI MCB Study Section 2006
NCI P01 Discovery and Development SEP Study Section 2006
NIA PO1 Special Study section 2007-10
NIA NAME study Section 2008-12
RC1/RC2 reviewer 2009
NICHD Special Emphasis panel 2010
NIA CMAD study Section member 2014-18
Chair - AFAR Young Investigator Grant Review Committee 2015-2020

Congress Organizing Committees

2nd International Symposium on Prostate Growth 1995
The GRS Consensus Meeting on GHD, Eilat, 1998
5th International IGF Symposium 1999
The IGF in Cancer Symposium, Boston 1999
Third International IGFBP Symposium, Sydney Australia 2000
GH Research Society Meeting Gothenburg 2000
The GRS Consensus Meeting on GH safety, Keswick 2001
The 1st Joint IGF Society and GH Research Society Meeting Boston 2002
The Nobel Institute IGFBP Symposium, Stockholm 2003
The 2nd Joint IGF Society and GH Research Society Meeting, Cairns 2004
The 3rd Joint IGF Society and GH Research Society Meeting, Kobe 2006
Chair: The LWPES/ESPE/GRS Consensus Meeting on ISS, Los Angeles, 2007
The 4th Joint IGF Society and GH Research Society Meeting, Genova, 2008
Chair: The First Western DERC Awardee Conference, La Jolla 2009
The 5th Joint IGF Society and GH Research Society Meeting, New York, 2010
Chair: Aging in Asia-Pacific APRU-Meeting, Los Angeles 2013
The GRS Workshop on GH safety, Manchester 2014
Co-Chair: The GRS Workshop on Long Acting GH Product Development, Palo Alto 2015
The GRS Workshop on GH use in Children, Lisbon 2019

Membership in Professional and Scientific Societies (and offices held):

Growth Hormone Research Society (*President 2014*)
Society for Pediatric Research (Elected 1995)
American Pediatric Society (Elected 2006)
International IGF Society (*Executive Committee Member – 2000-2009*)
Pediatric Endocrine Society (*Member, Various Committees*)
Association of Program Directors in Endocrinology (*Board Member 1999-2005*)
Endocrine Society (*Member, Various Committees*)
American Diabetes Association (Career Development Awardee)
Gerontological Society of America (Elected Fellow)
American Society of Aging (*Member Board of Directors*)

Patents:

- Compositions to prevent and treat type-1 diabetes. US 7,998,928 (**granted 2012**)
- Treatment of Type 2 Diabetes, Metabolic Syndrome, Myocardial Injury and Neurodegeneration with Humanin and Analogs Thereof. US 8,309,525 (**granted 2013**)
- Small humanin-like peptides. WO2009135165-A2, US20110039771, WO2009135165A3, US 8,637,470 (**granted 2014**)
- MOTS-c peptide in metabolism US-10,064,914B2 (**granted 2018**)
- MENTSH analogues as therapeutics for diabetes, obesity, and their associated diseases and complications (**pending**)

Founder and Director:

CohBar Inc., a mitochondrial peptide biotechnology company (NASDAQ: CWBR)
MENTSH Therapeutics Inc., a precision medicine biotechnology company

Media Mentions and Appearances:

New York Times
Los Angeles Times
BBC
Scientific American
ABC news
Washington Post
Medscape
Bloomberg News
Next Avenue
Forbes

Editorial Positions:

Associate Editor	2003-10	<i>Pediatric Research</i>
Associate Editor	2006-10	<i>Growth, Growth Hormone, & Metabolism</i>
Associate Editor	2006-10	<i>PLoS Computational Biology</i>
Associate Editor	2008-12	<i>Journal of Pediatric Endocrinology</i>
Associate Editor	2010-12	<i>Frontiers in Pediatric Endocrinology</i>
Associate Editor	2011-14	<i>International Journal of Genetics and Gene Therapy</i>

Editorial Board Member:

1995-97	Growth Regulation
1999-13	Journal of Clinical Endocrinology and Metabolism (3 rd term)
1999-14	Growth Hormone and IGF Research (3 rd term)
1999-12	Molecular Genetics and Metabolism (3 rd term)
2000-01	YourDoctor.com (Diabetes Section Editor)
2001-09	Endocrinology (2 nd term)
2001-12	Journal of Pediatric Endocrinology & Metabolism (3 rd term)
2001-06	Cancer Biology and Therapy
2001-07	Biocritique
2003-08	Growth and Genetics
2006-12	Journal of Clinical Pediatric Endocrinology (2 nd term)

Reviewer (Partial list): *New England Journal of Medicine, Lancet, Journal of Clinical Investigation, Journal of Biological Chemistry, JAMA, Journal of the National Cancer Institute (JNCI), Proceedings of the National Academy of Sciences (PNAS), Genes & Development, Diabetes, Molecular Endocrinology, Cancer Research, FASEB, PLoS Biology, Molecular and Cellular biology, Aging Cell, Science, Cell Metabolism.*

Commentator: *Journal of National Cancer Institute, Pediatric Research, Endocrine News, Endocrine today, Journal of Molecular Medicine, AARP magazine.*

Academic Committees

1999-12	UCLA Research Advisory Committee
2000-12	UCLA Committee on Appointments and Promotions
2000-12	UCLA General Clinical Research Center (& CTSI) Advisory Committee
2003-12	Chair, UCSD/UCLA Diabetes Research Center Executive Committee
2010-12	UCLA CHRCDA Internal Advisory Committee (Co-Chair)
2012-	Provost Research Committee, University of Southern California
2012-	CTSI advisory Committee, University of Southern California
2016-	Chair, Provost Task Force on Lifespan Health and Longevity
2020-	Chair, USC Public Health Policy Advisory Committee

Mentor/PI on Training Grants: - (total direct costs)

1993-1995 NRSA for L Katz "IGFs in the beta cell" \$66,000
1995-1996 LWPES fellowship for L Katz "IGF and the beta cell survival" \$35,000
1996-1999 CAP Award for L Katz "IGFs in the treatment of diabetes" \$270,000
1996-1997 NRSA for S Weinzimer "IGFBP partners" \$33,000
1997-1998 LWPES fellowship for S Weinzimer "Cloning IGFBP-3 partners" \$35,000
1998-1999 CHRC Award for S Weinzimer "Transferrin – IGFBP-3 interactions" \$35,000
1997-1998 NRSA for A Grimberg "IGFBPs and apoptosis" \$66,000
1998-1999 LWPES fellowship for A Grimberg "IGFBP-3 mediates p53 effects" \$35,000
1998-1999 NRSA for R Ferry "IGFBP-3 in the beta cell" \$66,000
1999-2000 LWPES fellowship for R Ferry "IGFBP-3 in type 1 diabetes" \$35,000
2000-2001 CHRC Award for R Ferry "IGFBPs in the beta cell" \$50,000
2001-2006 KO8 Award for R Ferry "Growth factors in beta cells" \$600,000
1997-1998 NRSA for M Shim "IGFBPs and insulin resistance" \$33,000
2000-2002 Glaser-GPRN fellowship for M Shim "GH treatment of CP" \$112,000
1999-2000 NRSA for L Wetterau "Activation of telomerase by IGFs" \$35,000
2000-2001 LWPES fellowship for L Wetterau "IGFs and telomerase" \$35,000
2001-2003 Giannini Award for K Lee "TR3 and IGFBP-3" \$80,000
2003-2005 PSDP for K Bharucha "IGFBPs in the regulation of insulin action" \$140,000
2003-2005 CHRC for KW Lee "IGFBP-3 and Nur77" \$225,000
2005-2007 DOD Fellowship Award for L Cobb "IGFBP-3 Phosphorylation" \$180,000
2005-2006 LWPES fellowship for J Yang "GH-IGF system in IUGR" \$35,000
2005-2006 LWPES Scholar Award for KW Lee "IGFBP-3 action" \$35,000
2005-2006 T32 fellowship for R Randhawa "Epigenetics of IGF2 IUGR" \$40,000
2006-2007 T32 fellowship for J Ching "Humanin in cancer" \$45,000
2006-2009 DOD Career Development Award for KW Lee "IGFBP-3 in CaP" \$500,000
2006-2007 ESPE Sabbatical grant for I Netchine "IGF & Fetal growth" \$50,000
2008-2009 T32 fellowship for J Keni "regulation of humanin kinetics" \$50,000
2008-2009 NRSA fellowship for P Hoang "Humanin Rx of T1DM" \$50,000
2009-2010 T32 fellowship for E Hosono "SHLPs in diabetes" \$50,000
2010-2011 T32 fellowship for B Miyazaki "Novel metabolic effects of MDPs" \$50,000
2011-2012 T32 fellowship for DC Lee "humanin protection from environmental toxins" \$50,000
2012-2013 AFAR fellowship for K Yen "Mitochondrial peptides and aging in worms" \$50,000
2012-2013 PES Award for YP Chin: The mitochondria in diabetes complications \$35,000
2013-2017 Ellison Foundation New Scholar in Aging for DC Lee "MOTS-c in aging" \$800,000
2016-2018 AFAR fellowship for S Kim "Humanin regulation of autophagy" \$100,000
2018-2020 T32 pre-doc fellowship for B Miller "MDPs in neurodegeneration" \$100,000
2019-2021 Japan Research Society Fellowship for H Kumagai "MOTS-c and Exercise" \$100,000

Principal Investigator of Grants: (Past) - (total direct costs)

1989-1991 Juvenile Diabetes Foundation "IGF-I Therapy in Diabetes" \$60,000
 1990-1992 American Diabetes Association "IGF-I Treatment of NIDDM" \$70,000
 1992-1994 CHRC Award "Biological Actions of IGFs" \$70,000
 1992-1996 NIH NCI RO1 CA58110 "The IGF axis in prostate carcinogenesis" \$500,000
 1993-1996 NIH 1RO1 DK47591 "IGF axis abnormalities in BPH" \$400,000
 1993-1996 ADA Career Development Award "The IGF axis in the beta cell" \$300,000
 1995-1999 FDA-RO1-01181 "IGF-I therapy of Congenital Hyperinsulinism" \$300,000
 1996-2001 NIH 1P50 HL 56401 "IGFs in Lung Development and BPD" \$780,000
 1996-2001 NIH 2RO1 DK47591 "IGF Axis Abnormalities in BPH" \$580,000
 1999-2002 American Cancer Society TPRN-N5 "IGFBP-3 in Prostate Apoptosis" \$225,000
 2000-2002 Pfeiffer Foundation "*In vitro* Models of Prostate Cancer" \$75,000
 1999-2002 JDFI "Novel Approaches to Preventing Diabetes Complications" \$300,000
 1999-2003 DOD CS-22982 "Signaling pathways in Prostate Cancer" \$480,000
 1998-2003 NIH 1RO1 AI40203 "The IGF axis in asthma" \$750,000
 1999-2003 CaP CURE Award "The IGF/IGFBP-3 axis in CaP" \$300,000
 2000-2003 NIH SBIR Award (with Celtrix Inc) "IGFBP-3 Therapy of Cancer" \$300,000
 2001-2003 Cerebral Palsy Foundation "GH therapy in Cerebral Palsy " \$100,000
 2000-2004 NCI UO1-CA 84128 "Novel Models of Prostate Cancer" \$360,000
 2001-2004 P30 AG16570 UCLA ADRC "Pilot Project on humanin" \$30,000
 2001-2005 Novo Nordisk "IGF-based dose titration of GH " National PI \$100,000
 2005-2007 NIH R21 CA 121220 Humanin in Prostate Cancer \$300,000
 2001-2006 NIA R01AG20954 Genomic and non-genomic actions of IGFBP-3 \$900,000
 2006-2009 Eli Lilly "Development of a D3GHR Chemotyping assay " \$100,000
 2006-2009 Amgen "IGF1R blockade in prostate cancer " \$200,000
 2006-2008 JDRF Idea Development "Prevention of diabetes with humanin" \$125,000
 2003-2008 1R01CA100938 "IGF-I: a nutritionally regulated target in prostate cancer" \$1,000,000
 2005-2008 DOD PC050485 "Humanin: a novel therapeutic target in prostate cancer" \$375,000
 2008-2010 Genentech Foundation "Proteomic Discovery of GH-dependent markers " \$100,000
 2004-2010 R01HD047013 "Role of IGF2 in Fetal Growth Restriction " \$1,500,000
 2002-2018 NCI P50CA92131 (Project PI) "SPORE in Prostate Cancer" \$1,500,000
 2003-2017 NIDDK 2P30DK063491 Diabetes Research Center \$9,000,000
 2007-2012 NIA 1P01AG027734 (Project PI) "GH & IGF exceptional longevity" \$500,000
 2006-2016 K12 HD034610 (Training Director) UCLA CHRC \$4,000,000
 2011-2013 NIDDK 1R21DK089447 "Humanin and Type 2 Diabetes" \$250,000
 2011-2013 Glen Foundation PC441372 "Mitochondrial Peptides in Aging" \$60,000
 2009-2014 NIA 1R01AG 034430 (EUREKA Award) "MDPs in aging" \$800,000
 2009-2014 NIA 1R01AG 035114 "Regulators of Glucose Homeostasis in Aging" \$100,000
 2009-2016 NIGMS 1R01GM 090311 (Transformative-RO1 Award) \$2,000,000
 2011-2016 NIEHS 5R01ES020812 (MDPs as Biomarkers of Environmental Toxins) \$1,250,000

Principal Investigator of Grants: (Active)

- 2018-2023 **R01AG061834** (Cohen)
 “Humanin is an AD resilience factor through its interaction with APOE4”
 Total direct costs: \$2,100,000.
- 2017-2020 **DOD PC160353** PI: Cohen.
 “Ethnic Disparity of the Mitochondrial Peptides and Prostate Cancer Risk”
 Total direct costs: \$600,000.
- 2017-2020 **AFAR BIG AWARD** PI: Cohen.
 “Characterization of the Healthspan promoting Activity of Humanin”
 Total direct costs: \$200,000.
- 2019-2020 **1R56AG062693-01** (Cohen/Crimmins)
Ethnic-Specific Mitochondrial DNA Variations that Contribute to Dementia
 Total direct costs: \$290,000.
- 2011-2022 **P01AG034906** PI: V. Longo (USC). Dr. Cohen is Co-PI
 “Dietary Restriction, GH/IGF-I & Mechanisms of Differential Cellular Protection”
 Dr. Cohen leads a project on humanin in aging
 Total direct costs: \$14,500,000. Total costs of Dr. Cohen’s project: \$2,325,000
- 2018-2020 **Supplement to P01AG034906** Project-2. Total direct costs to Cohen: \$250,000
- 2018-2021 **U54CA233465** (Carpten).
“FLORIDA-CALIFORNIA CANCER RESEARCH HEALTH EQUITY CENTER”
 Dr. Cohen leads a project on MDPs in minority cancers
 Total costs of Dr. Cohen’s project: \$800,000
- 2019-2021 **Supplement to U54CA233465** Project-1. Total direct costs to Cohen: \$250,000
- 2018-2023 **R01EY27363** (Kenney). Dr. Cohen is a co-investigator with a subcontract
 “Protective Effects of Humanin on AMD Mitochondria”
 Total costs of Dr. Cohen’s project: \$125,000
- 2018-2023 **R01CA231219** (Aronson). Dr. Cohen is Co-PI
 “GPR120 and Macrophages in Dietary Omega-3 Inhibition of Prostate Cancer”
 Total costs of Dr. Cohen’s project: \$125,000

PENDING:

- 2020-2025 **P30AG068345** (Cohen, Verdin, Lithgow, and Curran, MPIs)
 “The University of Southern California and Buck Institute Nathan Shock Center”
 Total costs of project: \$4,000,000

Students and Post-Doctoral Fellows Supervised

1992-1999 University of Pennsylvania

1999-2012 UCLA

2012- USC

*Denotes – trainee received independent funding post-training

Trainee's Name	Degree	Institution	Year	Position in Cohen Lab	Years supervised	Funding Source	Current Position
Lorraine Katz*	M.D.	Columbia U.	1989	Fellow	1992-1996	LWPES	Prof U Penn
Michael Agus*	M.D.	U Penn	1995	Med student	1994-1995	NIH	Prof Harvard
Tara Beers*	Ph.D.	U Penn	1998	PhD student	1995-1998	T32	Medical writer
S Weinzimer*	M.D.	Yale	1992	Fellow	1995-1998	LWPES	Yale (Prof)
A. Grimberg*	M.D.	Cornell	1992	Fellow	1996-1999	LWPES	Penn (Prof)
Robert Ferry*	M.D.	UT	1994	Fellow	1997-2000	LWPES	UTSA (Prof)
Melanie Shim*	M.D.	Stanford	1995	Fellow	1999-2001	GPRN	Adj-Prof UCLA
M Moore*	M.D.	UCLA	2002	Med student	1999-2002	STAR	Prof Indiana U
Malik Francis*	B.Sc.	UCLA	2000	PhD student	2000-2004	NIH	Fellow Berkeley
Kuk-Wha Lee*	MD PhD	Loma Linda	1997	Fellow	2000-2003	Giannini	Prof UCLA
K Bharucha*	MD PhD	Yale	1998	Fellow	2002-2005	PSDP	Genentech
Makoto Anzo*	M.D.	Keio	1992	Post-Doc	2003-2006	NIH	Prof Keio
Joshua Yang*	M.D.	Texas Tech	2000	Fellow	2003-2006	LWPES	USF adj. prof
Ken Miyako*	MD PhD	Fukuoka U.	1999	Post-doc	2004-2007	NIH	Prof Kyushu
Laura Cobb*	Ph.D.	Cambridge	2004	Post-Doc	2004-2007	DOD	VP CohBar
Hae Soon Kim*	M.D.	Seoul U.	1980	Sabbatical	2005-2006	NIH	Professor EU
S. Koyama*	M.D.	Tokyo U.	2000	Post-Doc	2006-2009	NIH	Prof TU
Irene Netchine*	M.D.	INSERM	1990	Sabbatical	2006-2007	INSERM	Prof, INSERM
Haruo Mizune*	MD PhD	Nagoya U.	1996	Post-Doc	2007-2008	NIH	Chiba Prof
Pauli Yamada*	Ph.D.	UA	2007	Post-Doc	2007-2010	NIH	U Hawaii ass prof
I. Hernandez*	M.D.	U of Chile	2000	Post-Doc	2007-2008	NIH	Prof Santiago U
Brian Miyazaki*	<u>M.D.</u>	UCLA	2006	Fellow	2009-2012	T32	USC (Asst. Prof)
Qinglei Gao*	MD PhD	Beijing U	2003	Post-doc	2010-2012	NIH	Tongji U. Prof
YP Chin*	M.D.	UT SW	2007	Fellow	2010-2012	T32	UCLA (Asst. Prof)
David Lee*	Ph.D.	USC	2010	Post-Doc	2010-2012	T32	USC (Asst. Prof)

Trainee's Name	Degree	Institution	Year	Position in Cohen Lab	Years supervised	Funding Source	Current Position
G. Alvarez*	M.D.	USC	2008	Fellow	2011-2013	T32	USC (Asst. Prof)
Kelvin Yen*	Ph.D.	U Mass	2010	Post-Doc	2011-2013	AFAR	USC (Asst. Prof)
Su-Jeong Kim*	Ph.D.	Seoul NU	2013	Post-Doc	2013-2018	AFAR	USC (fellow)
Joyce Xiao	B.Sc.	UC London	2013	Pre-Doc	2013-2018	NIH	Res. Assoc @ WR
Brendan Miller	B.Sc.	Arizona SU	2015	Pre-Doc	2016-2020	T32	USC (student)
Hiroshi Kumagai	Ph.D.	Juntendo U	2017	Post-Doc	2019-2021	NIH	USC (fellow)
Jiali Liu	Ph.D.	Xian Univ.	2017	Post-Doc	2019-2021	NIH	USC (fellow)
Wang Xiang	B.Sc.	Harbin Univ.	2019	Pre-Doc	2019-2024	NIH	USC (student)
Ana Silverstein	B.Sc.	UW	2020	Pre-Doc	2020-2025	NIH	USC (student)
Melanie Flores	B.Sc.	Cal Poly	2020	Pre-Doc	2020-2025	NIH	USC (student)

Major Invited Lectures:

- Feb 1992 WSPR. Carmel, California. David W. Smith Award Lecture:
"IGF-II Hyper-expression in Prostate Fibroblasts from BPH Patients".
- May 1992 Lawson Wilkins Society Meeting. Baltimore, Maryland. Lilly Award Lecture:
"Effects of IGFBPs on Cell Growth".
- May 1993 Spanish Endocrine Society National Meeting. Seville, Spain.
"Growth Hormone Receptor Deficiency".
- May 1994 Workshop on GH and Catabolic Illness. Nice, France.
"Which actions of growth hormone are mediated by IGF-I and which are not".
- Oct 1995 3rd International Symposium on IGFBPs. Tübingen, Germany.
"IGFBP proteases - functional regulators of cellular growth".
- Sep 1996 NIH Research Festival Symposium. Bethesda MD.
"Regulation of cell growth and death by IGFBPs"
- Mar 1997 Invited lecturer: Parapathetic Club.
"IGFBPs as cell regulators".
- Apr 1997 NIH Conference on Assessment of the GH/IGF-I axis in aging, Wash. DC.
"IGFBP-3 and prostatic neoplasia"
- Jun 1998 Endocrine Society Plenary Symposium. New Orleans LA.
"Cell Regulatory Function of IGFBP-3"
- Aug 1998 Cap CURE Annual Meeting. Lake Tahoe, CA
Lecture: "Novel aspects of prostatic IGF Biology"
- Sep 1999 The First International Symposium on GH, IGF, and Cancer, Boston.
Lecture: "Cancer risk-reduction by Monitoring IGF-I during GH therapy"
- May 2000 GRS consensus meeting on Growth Hormone Safety, Keswick VA.
Lecture: "Epidemiology of GH and Cancer."
- Sep 2000 Cap CURE Annual Meeting. Lake Tahoe, CA
Lecture: "IGFBP-3: a potential therapy for prostate cancer"
- Nov 2000 ICE 2000, Sydney Australia.
Lecture: "GH, IGF and diabetes: safety implications for clinicians"
- May 2001 International Growth Symposium, Cancun, Mexico.
Lecture: "What are IGFBPs doing in the nucleus?"
- May 2002 NIH meeting on GH, IGF and Aging.
"Role of the GH-IGF-IGFBP system in carcinogenesis".
- Dec 2002 NCI Prostate SPORE Annual meeting, San Francisco.
"IGFBP-3 and its Role in Prostate Cancer".

- Apr 2003 NIH apoptosis and aging workshop, Bethesda MD.
Lecture: "intra-nuclear roles of IGFBP-3 in apoptosis"
- May 2003 SPR meeting, Seattle, WA, Plenary Symposium on peri-natal origins of disease.
Lecture: "implications of early childhood growth on adult cancer risk"
- Aug 2003 The Fifth International IGFBP Symposium, Stockholm, Sweden.
Plenary Lecture: "The Ying and Yang of IGFBP-3"
- Nov 2003 Gerontological Society of America Annual Meeting, San Diego, CA.
Lecture: "IGF and longevity in humans"
- Dec 2003 The Annual Meeting of the Asian Endocrine Society, Singapore.
Plenary Lecture: "Clinical and molecular aspects of the IGFBPs"
- Jun 2004 Annual Somatomedin Club, New Orleans, LA
Keynote Lecturer: the year in IGF science
- Jun 2004 Transpacific Lecture, Satellite Symposium to ENDO2004 New Orleans, LA
Lecture: "Humanin – a new growth factor"
- Jan 2005 Gordon Research Conference Ventura CA
"Mechanisms of action of IGFBPs"
- Jun 2005 Endocrine Society Annual Meeting Symposium. San Diego, CA
"IGF-based Dosing Optimizes the Efficacy of GH Therapy"
- Jul 2005 NICHD grantee meeting, Bethesda MD
Lecture: "IGF2 epigenetics and fetal growth"
- Jan 2006 Gordon Research Conference on Aging Ventura CA
"IGF-related molecules in longevity and aging"
- Jan 2006 SPORE Annual Meeting, Houston Texas
"Mechanisms of IGFBP-3 actions as an anti-prostate cancer agent"
- May 2006 NIH Conference on Nuclear Receptors and Aging
Lecture: "IGFBP-3 interactions with nuclear receptors"
- Nov 2006 4th International Joint Meeting of the GRS and IGF-Society, Kobe, Japan
"Chemotype: The Interface Between Genotype and Phenotype"
- May 2007 American Pediatric Society Annual meeting, Toronto CA
APS Best Science Award Lecture: "Unraveling the functions of IGFBPs"
- Jun 2007 Endocrine Society Annual meeting, Toronto CA
Plenary Lecture: "The GH IGF axis in aging and Longevity"
- Dec 2007 AFAR symposium on Aging. Genome maintenance, and Metabolism
Lecture: "Growth factors, aging, and cancer"
- May 2008 LWPES/PAS Annual Meeting, Honolulu Hawaii
Lecture: Consensus Statement on ISS

- Oct 2008 15th Prostate Cancer Foundation Meeting, Lake Tahoe
IGFs Integrate Genetic and Environmental Signals to Control Longevity and Health
- Apr 2009 Milken Institute Global Conference
Lecture: Strategies for enhancing health span and life span
- Sep 2009 ESPE/LWPES Joint Meeting, New York
Plenary Lecture: GH, IGF, Aging and Longevity
- Sep 2009 Annual AFAR meeting, Santa Barbara
Keynote Lecture: Mitochondrial-derived peptides: retrograde signals for metabolism
- Mar 2010 The Kroc Professorship and Lecture, Stanford University
Lecture: Mitochondrial Peptides in Health and Disease
- May 2010 FDA Advisory Panel for EGRIFTA (Tesamorelin, a GHRH analogue), Rockville MD
Presentation: Managing Risks Associated with IGF-I Elevations
- Jun 2010 The Glenn Symposium on Aging, Harvard University
Lecture: Novel Mitochondrial Peptides and their role in aging
- Aug 2010 Gordon Research Conference on the Biology of Aging, Les Diablerets, Switzerland
Lecture: Longevity: insulin versus IGF pathways
- Nov 2010 National Diabetes Centers Director Meeting, NIH
Lecture: State of the Art: Pilot and Feasibility Grants
- Mar 2011 Cell Symposia – Metabolism and Aging – Cape Cod MA
Lecture: A novel family of mitochondrial-derived peptides in their role in Metabolism
- Jun 2011 Endocrine Society Annual Meeting, Boston MA - Plenary Lecture
Lecture: Humanin, MDPs, and the Expanding Role of the Mitochondria
- Oct 2011 Serono Symposium, Buenos Aires, Argentina - Plenary Lecture
Lecture: The mitochondria as an endocrine organelle
- Nov 2011 AFES Meeting, Ho Chi Minh City, Vietnam - Plenary Lecture
Healthy aging as a “cradle to grave” phenomena integrating genetics & lifestyle
- Feb 2012 Gordon Research Conference on Aging, Ventura CA
Lecture: “The role of the Mitochondria in Aging”
- Mar 2012 New Approaches to GH Treatment Meeting, Nice France
Lecture: “Personalized Medicine for GH: IGF-based Dosing”
- Mar 2012 ANSWER Investigator meeting, Dallas TX
Lecture: “Optimizing Pharmaco-economics of Growth Hormone Therapy”
- Mar 2012 AACE Annual meeting, Philadelphia PA
Lecture: “GH safety revisited 2012: Beyond SAGhE”
- Jun 2012 Glen Foundation Annual Meeting, Santa Barbara CA
Lecture: “Humanin and aging”

- Jun 2012 Endocrine Society Annual Meeting
Lecture: "IGF-based GH dosing is Dose Sparing and Safety-Enhancing"
- Jun 2012 Peking University, Institute for Population Health
Lecture: "Healthy Aging in the 21st Century"
- Nov 2012 Gerontological Society of America Annual Meeting, San Diego
Lecture: "Complex Relationships between growth hormone and aging"
- Nov 2012 World Congress on Insulin Resistance, Studio City
Lecture: "Humanin: a novel anti-diabetic, atherosclerosis-preventing peptide"
- Mar 2013 European Society of Bio-gerontology, Dead Sea, Israel
Lecture: "Mitochondrial Peptides and aging"
- Apr 2013 Milken Institute Global Conference, Los Angeles CA
Lecture: "The Longevity Economy – Riding the Demographic Wave"
- May 2013 Society of Pediatric Research, Wash DC
Lecture: "Consensus Statements and Guidelines for GH therapy"
- May 2013 USC Global Conference, Seoul, Korea
Lecture: "Challenges and Opportunities for aging in Asia"
- June 2013 IAGG, Seoul, Korea
Lecture: "humanin like peptides in aging and longevity"
- July 2013 Yamano College, Tokyo Japan
Lecture: "The Science of Aesthetics and Aging"
- Oct 2013 Bloomberg Longevity Economy Conference, New York
Lecture: "Opportunities in Personalized Aging"
- Nov 2013 NIH Common Fund High Risk-High Reward Symposium, Bethesda MD
Lecture: "Mitochondrial peptides and their roles in health and disease"
- Nov 2013 Gerontological Society of America Annual Meeting, New Orleans
Lecture: "Humanin: a new GH-dependent regulator of Aging"
- Mar 2014 Milhaupt Symposium of The PLATO Society, Los Angeles
Lecture: "Longevity in the 21st Century"
- Mar 2014 The National Lipid Association Meeting, Maui
Lecture: "Mitochondrial Peptides as Therapeutic Targets in Atherosclerosis"
- Apr 2014 Milken Institute Global Conference, Los Angeles CA
Lecture: "Personalized Aging"
- Jun 2014 American Aging Association 43rd Annual Meeting, San Antonio, Texas
Lecture: "Translational Aspects of Mitochondrial Peptides in Aging"
- Oct. 2014 The Brazilian Endocrine Society, Curitiba
Lecture: "Humanin is regulated by (and regulates) the GH-IGF axis"

- Nov. 2014 The Israel Alzheimer's Symposium
Lecture: "Novel roles of the mitochondria and Mitochondrial Peptides in AD"
- Jan. 2015 The Beckman Institute for Macular Research Annual Meeting
Lecture: "Mitochondrial Peptides - Drug Candidates for AMD"
- Mar 2015 The Gordon Conference on Oxidative Stress
Lecture: "Mitochondrial-Derived Peptides in Diseases of Aging"
- Mar 2015 Endocrine Society Annual Meeting
Lecture: "ISS – What it is and what it is not"
- Apr 2015 Milken Institute Global Conference, Los Angeles CA
Lecture: "Prescription for Wellness: Extending Our Health Span"
- Jun 2015 AGE Annual Meeting, Marina del Rey, CA
Lecture: "Advancing Translation in Aging Research"
- Jun 2015 Gavin Herbert Eye Institute *Bench to Bed* Symposium, Irvine, CA
Lecture: "Mitochondrial Peptides in Macular Degeneration"
- Oct 2015 USC Global Conference, Shanghai, China
Lecture: "Personalized Aging: The Nexus of Digital Technology and Genomic Science"
- Oct 2015 IAGG, Chiang Mai, Thailand
Lecture: "Enhancement of Healthspan by humanin"
- Dec 2015 Glenn Symposium, Einstein, New York.
Lecture: "Mitochondrial Peptides in Aging and Longevity"
- Feb 2016 Cedars Sinai Grand Rounds, Los Angeles.
Lecture: "Harnessing the Mitochondria to Treat Cancer"
- Mar 2016 Milken Institute Public Health Summit
Lecture: "A future of Healthy Aging"
- May 2016 NHLBI/NIDDK Mitochondrial Biology Symposium.
Lecture: "Mitochondrial Peptides and their role in metabolic processes"
- Aug 2016 Rejuvenation Biotechnology Conference, Novato, Ca.
Lecture: "Utilizing Mitochondrial Peptides to Extend Healthspan"
- Sep 2016 International Congress of Endocrinology, Beijing China.
Lecture: "The mitochondria in Aging"
- Nov 2016 American Physiological Society Integrative Biology of Exercise, Phoenix, AZ.
Lecture: "Mitochondrial Peptides Regulates Energy Homeostasis"
- Nov 2016 APPEP-JSPE Meeting, Tokyo, Japan.
Lecture: "The Future of Growth Hormone Therapy"
- Jan 2017 Keystone Symposia on Omics Strategies to Study the Proteome
Lecture: "Mitochondrial ORFomics and peptidomics"

- Mar 2017 National Institute of Environmental Health Sciences Keystone Lecture
Lecture: "The Mitochondria and the Environment"
- Mar 2017 2nd Interventions in Aging Conference, Cancun
Lecture: "New Insights into the Mitochondria and aging"
- Mar 2017 Gordon Research Conference, Ventura
Lecture: "Interface between the IGF axis and the Mitochondria"
- Apr 2017 ASPET Annual Meeting in Experimental Biology, Chicago
Lecture: "Mitochondrial-Derived Peptides: Physiology and Therapeutic Potential"
- May 2017 Milken Institute Global Conference, Los Angeles CA
Panel Discussion with Francis Collins and Elizabeth Blackburn: "Living to A healthy 100"
- May 2017 Keystone Symposia on Mitochondria, Metabolism, and the Heart
Lecture: "Mitochondrial-Derived Peptides and their Role in Vascular Disease"
- Jun 2017 Japanese Society of Gero-Dentology, Nagoya, Japan
Lecture: "Personalized Aging – Implication for Oral Health"
- Sep 2017 11th Congress of the International Society of Nutrigenetics and Nutrigenomics,
Lecture: "Nutrigenomics meets the Mitochondria"
- Oct 2017 The 8th Korea Healthcare Congress 2017
Lecture: "How Technology will Change Healthcare and Hospital Practice"
- Oct 2017 The National Investment Center for Seniors Housing & Care (NIC)
Lecture: "Genomics and drug development effects on memory care unit needs"
- Feb 2018 The 4th Annual USC Senior Living Executive Course
Lecture: "New Insights into dementia– Implications for Memory Care Planning"
- Mar 2018 Tulane University - The 46th Annual Schüeler Distinguished Lecture in Pharmacology
Lecture: "The Mitochondria in Health Disparity – Opportunities for Drug Development"
- April 2018 Oklahoma GeroScience Symposium
Lecture: "Mitochondria in Aging"
- April 2018 Yonsei University Mitochondrial Biology Symposium, Korea
Lecture: "Mitohormesis – a role for Mitochondrial-Derived Peptides?"
- April 2018 Japanese Endocrine Society
Lecture: "A kinesio-genomic SNP in MOTS-c is a diabetes risk factor in Japanese men"
- Jun 2018 American Aging Association Annual Meeting, Philadelphia
Lecture: "Mitochondrial-Derived Peptides: Novel Regulators in Diet and Exercise"
- Oct 2018 Barshop Symposium on Aging "Exercise Regulation of Biological Aging"
Lecture: "MOTS-c is a Biomarker of Physical Activity"
- Nov 2018 Gerontological Society of America, Boston.
Lecture: "MDPs: Novel Hormones That Regulate Metabolism During Aging"

- Feb 2019 International Conference on Frailty and Sarcopenia Research, Miami
Lecture: "Trends in Anti-Aging Research Aimed at Extending the Healthspan"
- Mar 2019 University of Coimbra, Portugal
Lecture: "Mitochondrial Biology as a Drug Discovery Platform"
- May 2019 American Aging Association Annual Meeting, San Francisco
Lecture: "Systems Biology of the Mitochondria in Aging"
- June 2019 G20 Meeting – Forum on Aging. Tokyo, Japan
Lecture: "Addressing the Challenges of an Aging Society Through Innovation"
- Sep 2019 International Perspectives on Geroscience, Weizmann Institute, Israel
Lecture: "Systems Biology of the Mitochondria: Tools for Discovery of Aging Targets"
- Nov 2019 The Irving S. Wright Award of Distinction Lecture. GSA Meeting, Austin
Lecture: "Endocrine Gerontology from IGFs to Mitochondrial Peptides"

Bibliography (comprising an h-index of 92, an i10 index of 261, with >27,000 citations):**MyBibliography can be accessed at**(for recent publications): <https://www.ncbi.nlm.nih.gov/pubmed/?term=Cohen+Pinchas%5BAuthor%5D>(for older publications): <http://1.usa.gov/1FL6bOu>My **Google-Scholar Page** can be accessed at: <http://scholar.google.com/citations?user=W1wn0zAAAAAJ&hl=en>**Research Publications, Peer Reviewed:**

1. Karnieli E, Cohen P, Barzilai N, Ish-Shalom Z, Armoni M, Rafaelov R, Barzilai D: Insulin resistance in Cushing syndrome. *Horm Metabol Res* 17:518, 1985.
2. Barzilai N, Cohen P, Barzilai D, Karnieli E: Increased insulin responsiveness and insulin clearance in thyrotoxicosis. *Isr J Med Sci* 21:722, 1985.
3. Cohen P, Barzilai N, Bar-Ilan R, Yassin K, Karnieli E: Lack of suppression of insulin secretion by hyperinsulinemia in a patient with an insulinoma. *J Clin Endocrinol and Metab* 63:1411, 1986.
4. Cohen P, Barzilai N, Barzilai D, Karnieli E: Correlation between insulin clearance and insulin responsiveness: studies in normal, obese, hyperthyroid, and Cushing syndrome patients. *Metabolism* 1986.
5. Karnieli E, Armoni M, Cohen P, Kantor Y, Rafaeloff R: Reversal of insulin resistance in diabetic rat adipocytes by insulin therapy. *Diabetes* 36:925, 1987.
6. Cohen P, Ariagno R, Tune B: Neonatal salicylism due to in utero aspirin overdose. *International Pediatrics* 4:352, 1989.
7. Cohen P, Harel C, Bergman R, Daud D, Pam Z, Barzilai N, Armoni M, Karnieli E: Insulin resistance and acanthosis nigricans: evidence for a post-receptor defect. *Metabolism* 39:1006, 1990.
8. Cohen P, Collart L, Prober CG, Fischer AF, Blaschke TF: Gentamicin pharmacokinetics in neonates undergoing extracorporeal membrane oxygenation. *Pediatr Infect Dis J* 9:562, 1990.
9. Szyzman P, Wolach B, Winaver J, Panett R, Cohen P, Shenkman L, Better OS: Nonazotemic hyperkalemia with renal and extra-renal defects in potassium transport: association with high levels of digoxin-like immunoreactive factor. *J Lab Clin Med* 116:315, 1990.
10. Cohen P, Barzilai N, Lerman A, Harel H, Szyzman P, Karnieli E: Insulin effects on glucose and potassium metabolism in-vivo: evidence for selective insulin resistance in humans. *J Clin Endocrinol Metab* 73:564-568, 1991.
11. Barzilai N, Cohen P, McIntyre N, Bar-Ilan R, Karnieli E: Increased insulin sensitivity in tumor hypoglycemia in a diabetic patient. *Am J Med Sci* 302:229-234, 1991.
12. Cohen P, Peehl DM, Lamson G, Rosenfeld RG: Insulin-like growth factors (IGFs), IGF receptors and IGF binding proteins in primary cultures of prostate epithelial cells. *J Clin Endocrinol Metab* 73:491-1991.
13. Barzilai N, Cohen P, Karnieli E, Einat R, Epstein O, Owan J, McIntyre N: In vivo insulin action in hepatocellular and cholestatic liver cirrhosis. *J Endo Invest* 14:727-735, 1991.
14. Hasegawa Y, Cohen P, Yorgin P, Rosenfeld RG: Characterization of urinary insulin-like growth factor binding proteins. *J Clin Endocrinol Metab* 74:830-835, 1992.

15. Cohen P, Graves HCB, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG: Prostate specific antigen (PSA) is an IGF binding protein (IGFBP-3) protease found in seminal plasma. *J Clin Endocrinol Metab* 75:1046-53; 1992.
16. Neely EK, Hintz RL, Parker B, Bachrach LB, Cohen P, Olney R, Wilson DW: Two-year treatment results of depot leuprolide acetate therapy for central precocious puberty. *J Pediatrics* 121:634-40, 1992.
17. Wilson DM, Dotson RJN, Neely EK, Cohen P, Hintz RL, Rosenfeld RG: A randomized trial of the effects of estrogen administration on serum growth hormone concentrations following stimulation with clonidine. *AJDC*, 147:63-6,1993.
18. Fielder PJ, Gargosky SE, Wilson K, Vaccarello M, Cohen P, Diamond F, Guevara-Aguirre J, Rosenbloom AL, Rosenfeld RG: Serum Profiles of IGFs and IGFBPs in Adults with Growth Hormone Insensitivity Syndrome (GHIS) Treated with IGF-I. *Acta Pediatr Scand* [Suppl], 82:40-43, 1993.
19. Cohen P, Peehl DM, Stamey TA, Wilson K, Clemmons DR, Rosenfeld RG: Elevated levels of insulin-like growth factor binding protein-2 in the serum of prostate cancer patients. *J Clin Endocrinol Metab*, 76:830-835, 1993.
20. Vaccarello MA, Diamond FB, Guevara-Aguirre J, Rosenbloom AL, Fielder PJ, Gargosky S, Cohen P, Wilson K, Rosenfeld RG. Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome. *J Clin Endocrinol Metab*, 77:273-80, 1993.
21. Barzilai N, Barzilai D, Karnieli E, Cohen P: Correlation Between Glucose and Amino Acids Disposal in Healthy and Hyperthyroid Subjects. *Horm Metabol Res*, 25:382-5, 1993.
22. Cohen P, Lamson G, Okajima T, Rosenfeld RG: Transfection of the human IGF binding protein-3 gene into Balb/c fibroblasts inhibits cellular growth. *Molecular Endocrinol*, 7:380-386, 1993. Also included the art for the Journal Cover
23. Lee DY, Cohen P, Krensky AM, Rosenfeld RG, Yorgin PD: Insulin-like growth factor binding protein-3 (IGFBP-3) protease activity in the urine of children with chronic renal failure. *Pediatr Nephrol*, 1993.
24. Cohen P, Peehl DM, Graves HCB, Rosenfeld RG: Biological effects of prostate specific antigen (PSA) as an IGF binding protein-3 (IGFBP-3) protease. *J Endocrinol*, 142:407-415, 1994.
25. Cohen P, Peele DM, Hintz RL, Rosenfeld RG: Insulin-like growth factor axis abnormalities in cultures of prostate stromal cells from patients with benign prostatic hypertrophy. *J Clin Endocrinol Metab*, 79:1410-1415, 1994.
26. Lee DY, Oh Y, Cohen P, Rosenfeld RG: Insulin-like growth factor binding protein-3 (IGFBP-3) protease activity in the urine of patients with chronic renal failure. *J Clin Endocrinol Metab*, 79:1376-1994.
27. KO Lee, Y Oh, P Cohen, DM Peehl, RG Rosenfeld. Identification of IGFBP-5 protease activity in human seminal plasma. *J Clin Endocrinol Metab*. 79:1367-1372. 1994.
28. Noveral J, A Bhala, Grunstein M, P Cohen. The insulin-like growth factor axis in airway smooth muscle cells. *American Journal of Physiology*, 267:L761-5, 1994.
29. Fielder PJ, Rosenfeld RG, Graves HCB, Grandbois K, Maack CA, Sawarama Y, Ogawa Y, Sommer A, Cohen P: Biochemical Analysis of PSA-proteolyzed IGFBP-3. *Growth Regulation*, 4:164-72. 1994.
30. Cohen P, Barzilai N, Karnieli E: Suppression of insulin secretion by C-peptide infusion in man. *Isr J Med Sci* 31:284-288;1995.

31. Hasegawa T, Cohen P, Rosenfeld RG: Characterization of the IGF axis in TM-3 Leydig cells. *Growth regulation* 5:151-9; 1995.
32. B Valentinis, A Bhala, R Baserga, P Cohen. Transfection of the human insulin-like growth factor (IGF) binding protein-3 gene into fibroblasts from IGF-receptor gene-targeted mice inhibits cellular growth. *Molecular Endocrinology* 9:361-367, 1995. Also included the art for the Journal Cover
33. Wilson K, Fielder PJ, Guevara JA, Cohen P, Rosenbloom A, Rosenfeld RG: Long term effects of IGF-I therapy on serum IGFs and IGFBPs in adolescents with GHRD. *Clinical Endocrinology*, 42:399-407, 1995.
34. P Cohen, A Bhala, Noveral J, Grunstein M. The effects of Leukotriene D₄ on the proliferation of airway smooth muscle cells are mediated by modulation of the IGF axis. *American Journal of Physiology* 296:L151-157; 1995.
35. Agus M, Katz L, Smith M, Hintz RL, Meadows A, Cohen P. Non-islet cell tumor hypoglycemia in a child with neuroblastoma: response to GH therapy. *Journal of Pediatrics*, 127:403-7; 1995.
36. Katz L, Hintz RL, Liu F, Cohen P. Non-islet cell tumor hypoglycemia in a child with neuroblastoma: analysis of the IGF axis. *Journal of Clinical Endocrinology and Metabolism* 81:1141-6; 1996.
37. Rajah R, Bhala A, Nunn S, Peehl D, Cohen P. Murine 7S nerve growth factor is an insulin-like growth factor binding protein protease. *Endocrinology* 137: 2676-2682; 1996.
38. Hawkins M, Barzilai N, Chen W, Angelov I, Hu M, Cohen P, Rossetti L: Increased Hexosamine availability similarly impairs the action of insulin and IGF-1 on glucose disposal. *Diabetes*. 45:1734-1743; 1996.
39. Rajah, R, Nunn S, Herrick D, Grunstein MM, Cohen P. LTD-4 induces matrix metalloproteinase-1, which functions as an IGFBP protease in airway smooth muscle cells., *American Journal of Physiology* L1014-1022; 1996.
40. Katz LEL, A Bhala, RL Hintz, P Cohen. IGF-II, IGFBPs and IGF-R in pancreatic beta cell lines. *Journal of Endocrinology* 152:455-464; 1997.
41. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. *Journal of Biological Chemistry* 272: 12181-12188; 1997.
42. Nunn S, Peehl DM, Cohen P: Cathepsin D is an acid activated IGFBP protease found in seminal plasma and produced in normal and malignant prostate epithelial cells. *Journal of Cellular Physiology* 171:196-204; 1997.
43. Gil-Ro Han, David F. Dohi, Ho-Young Lee, Roopmathy Rajah, Garrett L. Walsh, Waun Ki Hong, Pinchas Cohen, Jonathan M. Kurie. All-trans-retinoic acid increases TGF- β 2 and insulin-like growth factor binding protein-3 expression through a retinoic acid receptor- α -dependent signaling pathway. *Journal of Biological Chemistry* 272:13711-9; 1997.
44. Dong G, Rajah R, Vu T, Hoffman AR, Rosenfeld RG, CT Roberts Jr., Peele DM, Cohen P: Decreased expression of the Wilm's tumor suppressor gene WT1 and increased IGF-II and IGF-1R in the prostatic stroma of patients with benign prostatic hyperplasia. *Journal of Clinical Endocrinology and Metabolism*, 82:2198-2203; 1997.
45. Katz LEL, Satin-Smith M, Collett-Solberg P, Thornton PS, Baker L, Stanley CA, Cohen P. IGF binding protein-1 levels in the diagnosis of hypoglycemia caused by hyperinsulinism *Journal of Pediatrics* 131:193-9; 1997.

46. Thomas LN, Cohen P, Douglas RC, Lazier C, Rittmaster RS. IGF binding protein 5 is associated with involution of the ventral prostate in castrated and finasteride-treated rats. *Prostate* 1998; 35:273-278.
47. Bhala A, Harris MC, Zirin S, Corcoran L, Cohen P. Insulin-like growth factor axis parameters in sick hospitalized neonates. *Journal of Pediatric Endocrinology and Metabolism* 11, 451-459, 1998.
48. Collett-Solberg PF, Nunn SE, Beers-Gibson T, Cohen P. Identification of novel high molecular weight IGFBP-3 association proteins in human serum. *Journal of Clinical Endocrinology and Metabolism* 83:2843-2850, 1998.
49. Hasdai D, Rizza RA, Holmes DR Jr, Richardson DM, Cohen P, Lerman A. Insulin and insulin-like growth factor-I cause coronary vasorelaxation in vitro. *Hypertension* 1998; 32:228-234.
50. Hasegawa T, Hasegawa Y, Rosenfeld RG, Cohen P. IGFBP-4 accumulation is negatively correlated with growth rate in TM-3 cells. *Growth Hormone and IGF Research* 1998; 8:277-282.
51. Katz LE, Satin-Smith MS, Collett-Solberg P, Baker L, Stanley CA, Cohen P. Dual regulation of insulin-like growth factor binding protein-1 levels by insulin and cortisol during fasting. *Journal of Clinical Endocrinology and Metabolism* 83:4426-4430; 1998.
52. Miao ZR, Lin TK, Bongso TA, Zhou X, Cohen P, Lee KO. Effect of insulin-like growth factors (IGFs) and IGFbps on in vitro sperm motility. *Clin Endocrinol (Oxf)* 1998; 49:235-9.
53. Barzilai N, She L, Liu BQ, Vuguin P, Cohen P, Wang J, Rossetti L. Surgical removal of visceral fat reverses hepatic insulin resistance. *Diabetes* 1999; 48:94-98
54. Rajah R, Nachajon RV, Collins MH, Hakonarson H, Grunstein MM, Cohen P. Elevated levels of the IGF-binding protein protease MMP-1 in asthmatic airway smooth muscle. *Am J Respir Cell Mol Biol* 1999; 20:199-208.
55. Grimberg A, Satin Smith M, Cerri R, Cohen P. The "two-bag system" for variable intravenous dextrose and fluid administration: Benefits in diabetic ketoacidosis management. *J Pediatr* 134:376-380;1999.
56. Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. *Cancer Res* 1999; 59:2203-9.
57. Hasdai D, Nielsen MF, Rizza RA, Holmes DR Jr, Richardson DM, Cohen P, Lerman A. Attenuated in vitro coronary arteriolar vasorelaxation to insulin-like growth factor I in experimental hypercholesterolemia. *Hypertension* 1999; 34:89-95.
58. Beers-Gibson T, Cohen P. IGFBP proteolytic activity of the neutrophil proteases cathepsin G and elastase. *J GH & IGF Res* 9: 241-253; 1999.
59. Burren CP, Wanek D, Mohan S, Cohen P, Guevara-Aguirre J, Rosenfeld RG. Regulation of serum IGFBP-4, IGFBP-5 and ALS by GH but not IGF-I. *Acta. Paediatrica* 1999; 428[S1]:185-191.
60. Katz LEL, Ferry RJ Jr, Stanley CA, Collett-Solberg PF, Baker L, Cohen P. Suppression of insulin over-secretion by subcutaneous recombinant human IGF-I in children with congenital hyperinsulinism due to defective β -cell sulfonylurea receptor. *The Journal of Clinical Endocrinology & Metabolism* 1999; 84:3117-3124.
61. Sutkowski DM, Goode RL, Baniel J, Teater C, Cohen P, McNulty AM, Hsiung HM, Becker GW, Neubauer BL. Growth regulation of prostatic stromal cells by PSA. *J Natl Cancer Inst* 1999; 91:1663-9.
62. R. Rajah, A. Khare, P.D.K. Lee, and P. Cohen. IGFBP-3 is partially responsible for high serum induced apoptosis of PC-3 prostate cells. *J Endocrinol* 1999; 163:487-94.

63. Thomas LN, Wright AS, Lazier CB, Cohen P, Rittmaster RS. Prostatic involution in men taking finasteride is associated with elevated levels of IGF-binding proteins (IGFBPs)-2, -4, and -5. *Prostate*. 2000; 42:203-10.
64. Officers of the GH Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. *J Clin Endocrinol Metab* 2000; 85:3990-3.
65. Cohen P, Nunn S, Peehl DM. Transforming growth factor-beta induces growth inhibition and IGF-binding protein-3 production in prostatic stromal cells: abnormalities in cells cultured from benign prostatic hyperplasia tissues. *J Endocrinology*. 2000; 164:215-223.
66. Izhar U, Hasdai D, Richardson DM, Cohen P, Lerman A. Insulin and insulin-like growth factor-I cause vasorelaxation in human vessels in vitro. *Coron Artery Dis* 2000;11:69-76.
67. Cohen P, Rajah R, Rosenbloom J, Herrick DJ. IGFBP-3 mediates TGF-beta1-induced cell growth in human airway smooth muscle cells. *Am J Physiol Lung Cell Mol Physiol*. 2000; 278:L545-L551.
68. Mannhardt B, Weinzimer SA, Wagner M, Fiedler M, Cohen P, Jansen-Durr P, Zwerschke W. Human papillomavirus type 16 E7 oncoprotein binds and inactivates growth-inhibitory insulin-like growth factor binding protein 3. *Mol Cell Biol* 2000; 20:6483-95.
69. Sueoka N, Lee HY, Wiehle S, Cristiano RJ, Fang B, Ji L, Roth JA, Hong WK, Cohen P, Kurie JM. IGF binding protein-6 activates programmed cell death in non-small cell lung cancer cells. *Oncogene* 2000; 19:4432-6.
70. Sueoka N, Lee HY, Walsh GL, Fang B, Ji L, Roth JA, LaPushin R, Hong WK, Cohen P, Kurie JM. Insulin-Like Growth Factor Binding Protein-6 Inhibits the Growth of Human Bronchial Epithelial Cells and Increases in Abundance with All-trans-Retinoic Acid Treatment. *Am J Respir Cell Mol Biol* 2000; 23:297-303.
71. Liu B, Lee HY, Weinzimer SA, Powell DR, Clifford JL, Kurie JM, Cohen P. Direct Functional Interactions between Insulin-like Growth Factor-binding Protein-3 and Retinoid X Receptor-alpha Regulate Transcriptional Signaling and Apoptosis. *J Biol Chem* 2000; 275:33607-33613.
72. Officers of the GH Research Society. Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. *J Clin Endocrinol Metab* 2001; 86:1868-70.
73. Boyle BJ, Zhao XY, Cohen P, Feldman D. Insulin-like growth factor binding protein-3 mediates 1alpha, 25-dihydroxyvitamin-D3 growth-inhibition in the LNCaP prostate cancer cell line through p21/waf1. *J Urol* 2001; 165:1319-24.
74. Weinzimer SA, Beers Gibson T, Collett-Solberg PF, Khare A, Liu B, Cohen P. Transferrin Is an Insulin-Like Growth Factor-Binding Protein-3 Binding Protein. *JCEM* 2001; 86:1806-13.
75. Cohen P, G Bright, AD Rogol, AM Kapplegaard, Rosenfeld RG. Effects of dose and gender on the growth and growth factor response to GH in GH-deficient children: implications for efficacy and safety. *JCEM* 2002; 87: 90-98.
76. R Rajah, KW Lee, P Cohen. Insulin-like growth factor binding protein-3 (IGFBP-3) mediates TNF induced apoptosis: Role of Bcl-2 phosphorylation. *Cell growth & Differentiation* 2002; 13:163-71.
77. Lee HY, Chun KH, Liu B, Wiehle SA, Cristiano RJ, Hong WK, Cohen P, Kurie JM. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. *Cancer Res* 2002; 62:3530-7.

78. Grimberg A, Liu B, Bannerman P, El-Deiry WS, Cohen P. IGFBP-3 mediates p53-induced apoptosis during serum starvation. *Int. J. Oncol.* 2002; 21:327-35.
79. Sperling MA, Saenger PH, Ray Hintz, Tom Wilson, Rose SR, on behalf of the LWPES drug and therapeutic committee. Growth hormone treatment and neoplasia-coincidence or consequence? *J Clin Endocrinol Metab* 2002; 87:5351-2
80. Moran A, Jacobs DR Jr, Steinberger J, Cohen P, Hong CP, Prineas R, Sinaiko AR. Association between the Insulin Resistance of Puberty and the IGF-I/Growth Hormone Axis. *J Clin Endocrinol Metab* 2002; 87:4817-20.
81. Ngo TH, Barnard RJ, Tymchuk CN, Cohen P, Aronson WJ. Effect of diet and exercise on serum insulin, IGF-I, and IGFBP-1 levels and growth of LNCaP cells in vitro. *Cancer Causes and Control* 2002; 13:929–935.
82. Franklin SL, Ferry RJ Jr, Cohen P. Rapid Insulin-Like Growth Factor (IGF)-Independent Effects of IGF Binding Protein-3 on Endothelial Cell Survival. *J Clin Endocrinol Metab* 2003; 88:900-7.
83. Moore MG, Wetterau LA, Francis MJ, Peehl DM, Cohen P. Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells. *Int J Cancer* 2003; 105:14-9.
84. Liu B, Weinzimer SA, Beers-Gibson T, Mascarenhas D, Cohen P. Type I-alpha Collagen is an IGFBP-3 Binding Protein. *Growth Hormone & IGF Research* 2003; 13:89–97.
85. Ngo TH, Barnard RJ, Leung PS, Cohen P, Aronson WJ. Insulin-Like Growth Factor I (IGF-I) and IGF Binding Protein-1 Modulate Prostate Cancer Cell Growth and Apoptosis: Possible Mediators for the Effects of Diet and Exercise on Cancer Cell Survival. *Endocrinology* 2003; 144:2319-24.
86. Wetterau LA, Francis MJ, Ma L, Cohen P. Insulin-like growth factor I stimulates telomerase activity in prostate cancer cells. *J Clin Endocrinol Metab.* 2003; 88:3354-9.
87. Ngo TH, Barnard RJ, Cohen P, Freedland S, Tran C, DeGregorio F, Elshimali YI, Heber D, Aronson WJ. Effect of Isocaloric Low-fat Diet on Human LAPC-4 Prostate Cancer Xenografts in Severe Combined Immunodeficient Mice and the Insulin-like Growth Factor Axis. *Clin Cancer Res.* 2003; 9:2734-43.
88. Wilson TA, Rose SR, Cohen P, Rogol AD, Backeljauw P, Brown R, Hardin DS, Kemp SF, Lawson M, Radovick S, Rosenthal SM, Silverman L, Speiser P. Update of guidelines for the use of growth hormone in children: The Lawson Wilkins pediatric endocrinology society drug and therapeutics committee. *J Pediatr.* 2003; 143:415-21.
89. Ikonen M, Liu B, Hashimoto Y, Ma L, Lee KW, Niikura T, Nishimoto I, Cohen P. Interaction between the Alzheimer's survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis. *Proc Natl Acad Sci U S A.* 2003; 100:13042–13047. PMID: PMC240741.
90. Mikheev AM, Mikheeva SA, Liu B, Cohen P, Zarbl H. A functional genomics approach for the identification of putative tumor suppressor genes: Dickkopf-1 as suppressor of HeLa cell transformation. *Carcinogenesis.* 2004; 25:47-59.
91. Lee KW, Liu B, Ma L, Li H, Bang P, Koeffler HP, Cohen P. Cellular internalization of insulin-like growth factor binding protein-3 (IGFBP-3): Distinct endocytic pathways facilitate reuptake and nuclear localization. *J Biol Chem.* 2004; 279:469-76.
92. Licinio J, Caglayan S, Ozata M, Yildiz BO, De Miranda PB, O'Kirwan F, Whitby R, Liang L, Cohen P, Bhasin S, Krauss RM, Veldhuis JD, Wagner AJ, DePaoli AM, McCann SM, Wong ML. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. *Proc Natl Acad Sci U S A.* 2004; 101:4531-6.

93. Ikezoe T, Tanosaki S, Krug U, Liu B, Cohen P, Taguchi H, Koeffler HP. Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Antagonizes the Effects of Retinoids in Myeloid Leukemia Cells. *Blood*. 2004; 104:237-42.
94. Shim ML, Levitt Katz LE, Davis J, Dotzler WC, Cohen P, Ferry RJ Jr. Insulin-like growth factor binding protein-3 is a novel mediator of apoptosis in insulin-secreting cells. *Growth Horm IGF Res*. 2004; 14:216-25.
95. Shim ML, Moshang T Jr, Oppenheim WL, Cohen P. Is treatment with growth hormone effective in children with cerebral palsy? *Dev Med Child Neurol*. 2004; 46:569-71.
96. Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. *Mol Cell Biol*. 2004; 24:7275-83.
97. Rosen CJ, Ackert-Bicknell C, Beamer WG, Nelson T, Adamo M, Cohen P, Bouxsein ML, Horowitz MC. Allelic differences in a quantitative trait locus affecting insulin-like growth factor-I impact skeletal acquisition and body composition. *Pediatr Nephrol*. 2005; 20:255-60.
98. Silha JV, Gui Y, Mishra S, Leckstrom A, Cohen P, Murphy LJ. Overexpression of Gly56/Gly80/Gly81-Mutant IGFBP-3 in Transgenic Mice. *Endocrinology*. 2005; 146:1523-31.
99. Grimberg A, Coleman CM, Burns TF, Himelstein BP, Koch CJ, Cohen P, El-Deiry WS. p53-dependent and p53-independent induction of IGFBP-3 by DNA damage and hypoxia. *J Clin Endocrinol Metab*. 2005; 90:3568-74.
100. Park P, Cohen P. Insulin-like growth factor I (IGF-I) measurements in growth hormone (GH) therapy of idiopathic short stature (ISS). *Growth Horm IGF Res*. 2005;15:S13-20.
101. Lee KW, Ma L, Yan X, Liu B, Zhang XK, Cohen P. Rapid apoptosis induction by IGFBP-3 involves an IGF-independent nucleo-mitochondrial translocation of RXRalpha/Nur77. *J Biol Chem*. 2005; 280:16942-8.
102. Ferry Jr RJ, Cohen P, Levitt Katz LE. Pharmacodynamic Considerations with Recombinant Human Insulin-Like Growth Factor-I in Children. *Horm Res*. 2005; 63:220-227
103. Liu B, Lee KW, Li H, Ma L, Lin GL, Chandraratna RA, Cohen P. Combination therapy of insulin-like growth factor binding protein-3 and retinoid X receptor ligands synergize on prostate cancer cell apoptosis in vitro and in vivo. *Clin Cancer Res*. 2005;11:4851-6.
104. Freedland SJ, Aronson WJ, Trock B, Cohen P, Kane CJ, Amling CL, Presti JC Jr, Terris MK; Shared Equal Access Regional Cancer Hospital Database Study Group. Racial differences in prognostic value of adult height for biochemical progression following radical prostatectomy. *Clin Cancer Res*. 2005 Nov 1;11(21):7735-42.
105. Oh SH, Kim WY, Kim JH, Younes MN, El-Naggar AK, Myers JN, Kies M, Cohen P, Khuri F, Hong WK, Lee HY. Identification of IGFBP-3 as a Farnesyl Transferase Inhibitor SCH66336-Induced Negative Regulator of Angiogenesis in Head and Neck Squamous Cell Carcinoma. *Clin Cancer Res*. 2006; 12:653-61.
106. Oufattole M, Lin SW, Liu B, Mascarenhas D, Cohen P, Rodgers BD. RNA polymerase II binding subunit 3 (Rpb3), a potential nuclear target of IGFBP-3. *Endocrinology*. 2006; 147:2138-46.
107. Benini S, Zuntini M, Manara MC, Cohen P, Nicoletti G, Nanni P, Oh Y, Picci P, Scotlandi K. Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma. *Int J Cancer*. 2006; 119:1039-1046.
108. Colon E, Strand ML, Carlsson-Skwirut C, Wahlgren A, Svechnikov KV, Cohen P, Soder O. Anti-apoptotic factor humanin is expressed in the testis and prevents cell-death in leydig cells during the first wave of spermatogenesis. *J Cell Physiol*. 2006; 208:373-85.

109. Yakar S, Buxsein ML, Canalis E, Sun H, Glatt V, Gundberg C, Cohen P, Hwang D, Boisclair Y, Leroith D, Rosen CJ. The ternary IGF complex influences postnatal bone acquisition and the skeletal response to intermittent parathyroid hormone. *J Endocrinol.* 2006; 189:289-99.
110. Kobayashi N, Barnard RJ, Henning SM, Elashoff D, Reddy ST, Cohen P, Leung P, Hong-Gonzalez J, Freedland SJ, Said J, Gui D, Seeram NP, Popoviciu LM, Bagga D, Heber D, Glaspy JA, Aronson WJ. Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. *Clin Cancer Res.* 2006; 12:4662-70.
111. Muzumdar RH, Ma X, Fishman S, Yang X, Atzmon G, Vuguin P, Einstein FH, Hwang D, Cohen P, Barzilai N. Central and Opposing Effects of IGF-I and IGF-Binding Protein-3 on Systemic Insulin Action. *Diabetes.* 2006; 55:2788-96.
112. Cobb LJ, Liu B, Lee KW, Cohen P. Phosphorylation by DNA-Dependent Protein Kinase Is Critical for Apoptosis Induction by Insulin-Like Growth Factor Binding Protein-3. *Cancer Res.* 2006; 66:10878-10884.
113. Ali O, Shim M, Fowler E, Greenberg MM, Perkins D, Oppenheim W, Cohen P. Growth Hormone Therapy Improves Bone Mineral Density in Children with Cerebral Palsy: A preliminary Pilot Study. *J Clin Endocrinol Metab.* 2007; 92(3):932-7.
114. Kim HS, Ali O, Shim M, Lee KW, Vuguin P, Muzumdar R, Barzilai N, Cohen P. Insulin-Like Growth Factor Binding Protein-3 Induces Insulin Resistance in Adipocytes In Vitro and in Rats In Vivo. *Pediatr Res.* 2007; 61:159-164. Also included the art for the Journal Cover
115. Liu B, Lee KW, Anzo M, Zhang B, Zi X, Tao Y, Shiri L, Pollak M, Lin S, Cohen P. IGFBP-3 inhibition of prostate cancer growth involves suppression of angiogenesis. *Oncogene.* 2007; 26:1811-9.
116. Cohen P, Rogol AD, Howard CP, Bright GM, Kappelgaard AM, Rosenfeld RG; American Norditropin Study Group. Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study. *J Clin Endocrinol Metab.* 2007; 92:2480-6.
117. Clayton PE, Cianfarani S, Czernichow P, Johannsson G, Rapaport R, Rogol A, et al. Management of the Child Born Small for Gestational Age Child (SGA) through to Adulthood: A Consensus Statement of the International Societies of Paediatric Endocrinology and the Growth Hormone Research Society. *J Clin Endocrinol Metab.* 2007; 92:804-10.
118. Ho KK et al. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society and Endocrine Society of Australia. *Eur J Endocrinol.* 2007; 157: 695—700.
119. Lee KW, Cobb L, Ma L, Liu B, Milbrandt J, Cohen P. Contribution of the Orphan Nuclear Receptor Nur77 to the Apoptotic Action of IGFBP-3. *Carcinogenesis.* 2007; 28:1653-8.
120. Degraff DJ, Malik M, Chen Q, Miyako K, Rejto L, Aguiar AA, Bancroft DR, Cohen P, Sikes RA. Hormonal regulation of IGFBP-2 proteolysis is attenuated with progression to androgen insensitivity in the LNCaP progression model. *J Cell Physiol.* 2007; 213:261-8.
121. Ali O, Shim M, Fowler E, Cohen P, Oppenheim W. Spinal Bone Mineral Density, IGF-1 and IGFBP-3 in Children with Cerebral Palsy. *Horm Res.* 2007; 68:316-320
122. Barnard RJ, Leung PS, Aronson WJ, Cohen P, Golding LA. A mechanism to explain how regular exercise might reduce the risk for clinical prostate cancer. *Eur J Cancer Prev.* 2007; 16:415-21.

123. Raina K, Blouin MJ, Singh RP, Majeed N, Deep G, Varghese L, Glodé LM, Greenberg NM, Hwang D, Cohen P, Pollak MN, Agarwal R. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. *Cancer Res.* 2007; 67:11083-91.
124. Hwang DL, Lee PD, Cohen P. Quantitative ontogeny of murine insulin-like growth factor (IGF)-I, IGF-binding protein-3 and the IGF-related acid-labile subunit. *Growth Horm IGF Res.* 2008; 18:65-74.
125. Freedland SJ, Mavropoulos J, Wang A, Darshan M, Demark-Wahnefried W, Aronson WJ, Cohen P, Hwang D, Peterson B, Fields T, Pizzo SV, and Isaacs WB. Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. *Prostate.* 2008; 68:11-9
126. Suh Y, Atzmon G, Cho MO, Hwang D, Liu B, Leahy DJ, Barzilai N, Cohen P. Functionally significant insulin-like growth factor-I receptor mutations in centenarians. *PNAS*; 2008. 105:3438-42. PMID: PMC2265137.
127. Ding F, Li HH, Zhang S, Solomon NM, Camper SA, Cohen P, Francke U. SnoRNA Snord116 (Pwcr1/MBII-85) Deletion Causes Growth Deficiency and Hyperphagia in Mice. *PLoS ONE.* 2008; 3:e1709.
128. Kobayashi N, Barnard RJ, Said J, Hong-Gonzalez J, Corman DM, Ku M, Doan NB, Gui D, Elashoff D, Cohen P, Aronson WJ. Effect of low-fat diet on development of prostate cancer and Akt phosphorylation in the Hi-Myc transgenic mouse model. *Cancer Res.* 2008; 68:3066-73.
129. Torng PL, Lee YC, Huang CY, Ye JH, Lin YS, Chu YW, Huang SC, Cohen P, Wu CW, Lin CT. Insulin-like growth factor binding protein-3 (IGFBP-3) acts as an invasion-metastasis suppressor in ovarian endometrioid carcinoma. *Oncogene.* 2008; 27:2137-47.
130. Anzo M, Cobb LJ, Hwang DL, Mehta H, Said JW, Yakar S, LeRoith D, Cohen P. Targeted deletion of hepatic Igf1 in TRAMP mice leads to dramatic alterations in the circulating insulin-like growth factor axis but does not reduce tumor progression. *Cancer Res.* 2008; 68:3342-9. PMID: PMC2928555.
131. Jung Yoon Park JY, Cho MO, Leonard S, Calder B, Mian IS, Kim WH, Wijnhoven S, vanSteeg H, Mitchell J, vanderHorst GT, Hoeijmakers J, Cohen P, Vijg J, Suh Y. Homeostatic Imbalance between Apoptosis and Cell Renewal in the Liver of Premature Aging XpdTTD Mice. *PLoS ONE.* 2008; 3:e2346.
132. P Cohen, AD Rogol, CL Deal, P Saenger, EO Reiter, JL Ross, SD Chernausek, MO Savage, JM Wit on behalf of the 2007 ISS Consensus Workshop participants. Consensus Guidelines for the Diagnosis and Treatment of Children with Idiopathic Short Stature: A Summary Statement of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. *J Clin Endocrinol Metab* 93: 4210–4217, 2008.
133. Yakar S, Rosen CJ, Bouxsein ML, Sun H, Mejia W, Kawashima Y, Wu Y, Emerton K, Williams V, Jepsen K, Schaffler MB, Majeska RJ, Gavrilova O, Gutierrez M, Hwang D, Pennisi P, Frystyk J, Boisclair Y, Pintar J, Jasper H, Domene H, Cohen P, Clemmons D, Leroith D. Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism. *FASEB J.* 2009; 23:709-19.
134. Miyako K, Cobb LJ, Francis M, Huang A, Peng B, Pintar JE, Ariga H, Cohen P. PAPA-1 Is a Nuclear Binding Partner of IGFBP-2 and Modulates Its Growth-Promoting Actions. *Mol Endocrinol.* 2009; 23:169-75. PMID: PMC2646620.

135. Mavropoulos JC, Buschemeyer WC 3rd, Tewari AK, Rokhfeld D, Pollak M, Zhao Y, Febbo PG, Cohen P, Hwang D, Devi G, Demark-Wahnefried W, Westman EC, Peterson BL, Pizzo SV, Freedland SJ. The Effects of Varying Dietary Carbohydrate and Fat Content on Survival in a Murine LNCaP Prostate Cancer Xenograft Model. *Cancer Prev Res.* 2009; 6:557-65.
136. Lenders CM, Feldman HA, Von Scheven E, Merewood A, Sweeney C, Wilson DM, Lee PD, Abrams SH, Gitelman SE, Wertz MS, Klish WJ, Taylor GA, Chen TC, Holick MF; on behalf of the Elizabeth Glaser Pediatric Research Network Obesity Study Group. Relation of body fat indexes to vitamin D status and deficiency among obese adolescents. *Am. J. Clin. Nutr.* 2009; 90:459-67.
137. Fan Y, Menon RK, Cohen P, Hwang D, Clemens T, Digirolamo DJ, Kopchick JJ, Leroith D, Trucco M, Sperling MA. Liver-specific Deletion of the Growth Hormone Receptor Reveals Essential Role of GH Signaling in Hepatic Lipid Metabolism. *J Biol Chem.* 2009; 284:19937-44.
138. Cobb LJ, Mehta H, Cohen P. Enhancing the Apoptotic Potential of Insulin-like Growth Factor-Binding Protein-3 in Prostate Cancer by modulation of CK2 Phosphorylation. *Mol Endocrinol.* 2009; 23:1624-33. PMC2754899.
139. Muzumdar RH, Huffman DM, Atzmon G, Buettner C, Budagov T, Cui L, Einstein FH, Cobb LJ, Fishman S, Poduval A, Hwang D, Barzilai N, Cohen P. Humanin: A Novel Regulator of Peripheral Insulin Action. *PLoS ONE.* 2009; 4(7): e6334. PMID: PMC2709436.
140. Safdie FM, Dorff T, Quinn D, Fontana L, Wei M, Lee C, Cohen P, Longo VD. Fasting and cancer treatment in humans: A case series report. *Aging (Albany NY).* 2009; 1:988-1007. PMID: PMC2815756.
141. Glaser Pediatric Research Network Obesity Study Group. Metformin Extended Release Treatment of Adolescent Obesity: A 48-Week Randomized, Double-Blind, Placebo-Controlled Trial with 48-Week Follow-up. *Arch Pediatr Adolesc Med.* 2010;164:116-23.
142. Koyama S, Cobb LJ, Mehta HH, Seeram NP, Heber D, Pantuck AJ, Cohen P. Pomegranate extract induces apoptosis in human prostate cancer cells by modulation of the IGF-IGFBP axis. *Growth Horm IGF Res.* 2010; 20:55-62. PMC2815223.
143. Jia Y, Lee KW, Swerdloff RS, Hwang D, Cobb LJ, Sinha Hikim A, Lue YH, Cohen P, Wang C. The interaction of insulin-like growth factor binding protein-3 and bax in mitochondria promotes male germ cell apoptosis. *J Biol Chem.* 2010; 285:1726-32. PMC2804330
144. Lue Y, Swerdloff R, Liu Q, Mehta H, Sinha Hikim A, Lee KW, Jia Y, Hwang D, Cobb LJ, Cohen P, Wang C. Opposing Roles of Insulin-Like Growth Factor Binding Protein 3 and Humanin in the Regulation of Testicular Germ Cell Apoptosis. *Endocrinology.* 2010; 151:350-7.
145. Aronson WJ, Barnard RJ, Freedland SJ, Henning S, Elashoff D, Jardack PM, Cohen P, Heber D, Kobayashi N. Growth Inhibitory Effect of Low Fat Diet on Prostate Cancer Cells: Results of a Prospective, Randomized Dietary Intervention Trial in Men with Prostate Cancer. *J Urol.* 2010; 183:345-50. PMC3089950.
146. Glaser Pediatric Research Network Obesity Study Group. Intraperitoneal Fat and Insulin Resistance in Obese Adolescents. *Obesity (Silver Spring).* 2010; 18:402-9.
147. Lee C, Safdie FM, Raffaghello L, Wei M, Madia F, Parrella E, Hwang D, Cohen P, Bianchi G, Longo VD. Reduced Levels of IGF-I Mediate Differential Protection of Normal and Cancer Cells in Response to Fasting and Improve Chemotherapeutic Index. *Cancer Res.* 2010; 70:1564-72. PMID: PMC2836202.

148. Hoang PT, Park P, Cobb LJ, Paharkova-Vatchkova V, Hakimi M, Cohen P, Lee KW. The neurosurvival factor Humanin inhibits beta-cell apoptosis via signal transducer and activator of transcription 3 activation and delays and ameliorates diabetes in nonobese diabetic mice. *Metabolism*. 2010; 59:343-349. PMID: PMC2932671.
149. Cohen P, Germak J, Rogol AD, Weng W, Kappelgaard AM, Rosenfeld RG, on behalf of the American Norditropin Study Group. Variable Degree of Growth Hormone (GH) and Insulin-Like Growth Factor (IGF) Sensitivity in Children with Idiopathic Short Stature Compared with GH-Deficient Patients: Evidence from an IGF-Based Dosing Study of Short Children. *J Clin Endocrinol Metab*. 2010; 95:2089-98.
150. Buschemeyer WC 3rd, Klink JC, Mavropoulos JC, Poulton SH, Demark-Wahnefried W, Hursting SD, Cohen P, Hwang D, Johnson TL, Freedland SJ. Effect of intermittent fasting with or without caloric restriction on prostate cancer growth and survival in SCID mice. *Prostate*. 2010; 70:1037-43.
151. Konijeti R, Henning S, Moro A, Sheikh A, Elashoff D, Shapiro A, Ku M, Said JW, Heber D, Cohen P, Aronson WJ. Chemoprevention of prostate cancer with lycopene in the TRAMP model. *Prostate*. 2010; 70:1547-54. PMID: PMC2930120.
152. Bachar AR, Scheffer L, Schroeder AS, Nakamura HK, Cobb LJ, Oh YK, Lerman LO, Pagano RE, Cohen P, Lerman A. Humanin is Expressed in Human Vascular Walls and Has a Cytoprotective Effect against Oxidized LDL-Induced Oxidative Stress. *Cardiovasc Res*. 2010; 88:360-6. PMID: PMC2952532.
153. Williams NG, Interlichia JP, Jackson MF, Hwang D, Cohen P, Rodgers BD. Endocrine Actions of Myostatin: Systemic Regulation of the IGF and IGF Binding Protein Axis. *Endocrinology*. 2011; 152:172-80.
154. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng CW, Hwang D, Martin-Montalvo A, Saavedra J, Ingles S, de Cabo R, Cohen P, Longo VD. Growth Hormone Receptor Deficiency is Associated with a Major Reduction in Pro-Aging Signaling, Cancer and Diabetes in Humans. *Science Translational Medicine*. 2011; 3:70ra13. PMID: PMC3357623
155. Clemmons DR on behalf of workshop participants. Consensus Statement on the Standardization and Evaluation of Growth Hormone and Insulin-like Growth Factor Assays. *Clin Chem*. 2011; 57:555-9. PMID: Pending.
156. Mehta H, Gao Q, Galet C, Paharkova V, Wan J, Said JW, Sohn J, Lawson G, Cohen P, Cobb JL, Lee KW. IGFBP-3 is a Metastasis Suppression Gene in Prostate Cancer. *Cancer Res*. 2011; 71:5154-63. PMID: PMC3148406.
157. Mason EJ, Grell JA, Wan J, Cohen P, Conover CA. Insulin-like growth factor (IGF)-I and IGF-II contribute differentially to the phenotype of pregnancy associated plasma protein-A knock-out mice. *Growth Hormone and IGF Research*. 2011; 21:243-7 PMID: Pending.
158. Oh YK, Bachar AR, Zacharias DG, Kim SG, Wan J, Cobb LJ, Lerman LO, Cohen P, Lerman A. Humanin Preserves Endothelial Function and Prevents Atherosclerotic Plaque Progression in Hypercholesterolemic ApoE Deficient Mice. *Atherosclerosis*. 2011; 219:65-73.
159. Gray A, Aronson WJ, Barnard RJ, Mehta HH, Wan J, Said J, Cohen P, Galet C. Global IGFBP-1 deletion does not affect prostate cancer development in a c-Myc transgenic mouse model. *J Endocrinol*. 2011, 211:297-304.
160. Aronson WJ, Kobayashi N, Barnard RJ, Henning S, Huang M, Jardack PM, Liu B, Gray A, Wan J, Konijeti R, Freedland SJ, Castor B, Heber D, Elashoff D, Said J, Cohen P, Galet C. Phase II Prospective Randomized Trial of a Low-Fat Diet with Fish Oil Supplementation in Men Undergoing Radical Prostatectomy. *Cancer Prev Res (Phila)*. 2011; 4:2062-71.

161. Rosenfeld RG, Cohen P, Robison LL, Bercu BB, Clayton P, Hoffman AR, Radovick S, Saenger P, Savage MO, Wit JM. Long-term surveillance of growth hormone therapy. *J Clin Endocrinol Metab.* 2012; 97:68-72.
162. Zacharias DG, Kim SG, Massat AE, Bachar AR, Oh YK, Herrmann J, Rodriguez-Porcel M, Cohen P, Lilach O, Lerman LO, Lerman A. Humanin, a Cytoprotective Peptide, Is Expressed in Carotid Artherosclerotic Plaques in Humans. *PLoS ONE* 2012; 7:e31065.
163. Konijeti R, Koyama S, Gray A, Barnard RJ, Said JW, Castor B, Elashoff D, Wan J, Beltran PJ, Calzone FJ, Cohen P, Galet C, Aronson WJ. Effect of a low-fat diet combined with IGF-1 receptor blockade on 22Rv1 prostate cancer xenografts. *Mol Cancer Ther.* 2012; 11:1539-46.
164. Zhang X, Urbietta-Caceres VH, Eirin A, Bell CC, Crane JA, Tang H, Jordan K, Oh YK, Zhu XY, Korsmo MJ, Bachar AR, Cohen P, Lerman A, Lerman LO. Humanin prevents intra-renal microvascular remodeling and inflammation in hypercholesterolemic ApoE deficient mice. *Life Sci.* 2012; 91:199-206.
165. Cohen P, Rogol AD, Weng W, Kappelgaard AM, Rosenfeld RG, Germak J; The American Norditropin Study Group. Efficacy of IGF-based growth hormone (GH) dosing in non GH-deficient (non-GHD) short stature children with low IGF-I is not related to basal IGF-I levels. *Clin Endocrinol (Oxf).* 2013; 78:405-414.
166. Seligson DB, Yu H, Tze S, Said J, Pantuck AJ, Cohen P, Lee KW. IGFBP-3 Nuclear Localization Predicts Human Prostate Cancer Recurrence. *Horm Cancer.* 2013; 4:12-23.
167. Wan J, Atzmon G, Hwang D, Barzilai N, Kratzsch J, Cohen P. Growth Hormone Receptor (GHR) Exon 3 Polymorphism Status Detection by Dual-Enzyme-Linked Immunosorbent Assay (ELISA). *J Clin Endocrinol Metab.* 2013; 98:E77-81.
168. Klink JC, Tewari AK, Masko EM, Antonelli J, Febbo PG, Cohen P, Dewhirst MW, Pizzo SV, Freedland SJ. Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways. *Prostate.* 2013; 73:754-62.
169. Widmer RJ, Flammer A, Herrmann J, Rodriguez-Porcel M, Wan J, Cohen P, Lerman LO, Lerman A. Circulating humanin levels are associated with preserved coronary endothelial function. *Am J Physiol Heart Circ Physiol.* 2013; 304:H393-7. PMID: PMC3774506
170. Parrella E, Maxim T, Maialetti F, Zhang L, Wan J, Wei M, Cohen P, Fontana L, Longo VD. Protein restriction cycles reduce IGF-1 and phosphorylated Tau, and improve behavioral performance in an Alzheimer's disease mouse model. *Aging Cell.* 2013; 12:257-68. PMID: PMC3982836
171. Dean JP, Sprenger CC, Wan J, Haugk K, Ellis WJ, Lin DW, Corman JM, Dalkin BL, Mostaghel E, Nelson PS, Cohen P, Montgomery B, Plymate SR. Response of the Insulin-Like Growth Factor (IGF) System to IGF-IR inhibition and Androgen Deprivation in a Neoadjuvant Prostate Cancer Trial: Effects of Obesity and Androgen Deprivation. *J Clin Endocrinol Metab.* 2013; 98:E820-8.
172. Deal CL, Tony M, Höybye C, Allen DB, Tauber M, Christiansen JS; the 2011 GH in PWS Clinical Care Guidelines Workshop Participants. Growth Hormone Research Society Workshop Summary: Consensus Guidelines for Recombinant Human Growth Hormone Therapy in Prader-Willi Syndrome. *J Clin Endocrinol Metab.* 2013; 98:E1072-87
173. Jia Y, Lue YH, Swerdloff R, Lee KW, Cobb LJ, Cohen P, Wang C. The cytoprotective peptide humanin is induced and neutralizes Bax after pro-apoptotic stress in the rat testis. *Andrology.* 2013; 1:651-9.

174. Galet C, Gray A, Said JW, Castor B, Wan J, Beltran PJ, Calzone FJ, Elashoff D, Cohen P, Aronson WJ. Effects of calorie restriction and IGF-I receptor blockade on the progression of 22Rv1 prostate cancer xenografts. *Int. J. Mol. Sci.* 2013; 14:13782-95.
175. Lenders CM, Lee PD, Feldman HA, Wilson DM, Abrams SH, Gitelman SE, Klish WJ, Wertz MS, Taylor GA, Alongi RT, Chen TC, Holick MF; Elisabeth Glaser Pediatric Research Network Obesity Study Group. A cross-sectional study of osteocalcin and body fat measures among obese adolescents. *Obesity* (Silver Spring). 2013; 21:808-14.
176. Wit JM, Ranke MB, Albertsson-Wikland K, Carrascosa A, Rosenfeld RG, Van Buuren S, Kristrom B, Schoenau E, Audi L, Hokken-Koelega AC, Bang P, Jung H, Blum WF, Silverman LA, Cohen P, Cianfarani S, Deal C, Clayton PE, de Graaff L, Dahlgren J, Kleintjens J, Roelants M. Personalized Approach to Growth Hormone Treatment: Clinical Use of Growth Prediction Models. *Horm Res Paediatr.* 2013;79:257-70.
177. Rogol AD, Cohen P, Weng W, Kappelgaard AM, Germak JA. Prepubertal Children with Growth Hormone Deficiency Treated for Four Years with Growth Hormone Experience Dose-Dependent Increase in Height, but Not in the Rate of Puberty Initiation. *Horm Res Paediatr.* 2013; 80:28-37.
178. Chin YP, Keni J, Mehta H, Wan J, Anene F, Jia Y, Lue YH, Swerdloff R, Cobb LJ, Wang C, Cohen P. Pharmacokinetics and tissue distribution of humanin and its analogues in male rodents. *Endocrinology.* 2013; 154:3739-44.
179. Galet C, Gollapudi K, Stepanian S, Byrd JB, Henning SM, Grogan T, Elashoff D, Heber D, Said JW, Cohen P, Aronson WJ. Effect of a Low-fat Fish Oil Diet on Pro-Inflammatory Eicosanoids and Cell Cycle Progression Score in Men Undergoing Radical Prostatectomy. *Cancer Prev Res (Phila).* 2014; 7:97-104.
180. Cohen P, Weng W, Rogol AD, Rosenfeld RG, Kappelgaard AM, Germak J. Dose-Sparing and Safety-Enhancing Effects of an IGF-I-Based Dosing Regimen in Short Children Treated with Growth Hormone in a 2-Year Randomized Controlled Trial: Therapeutic and Pharmacoeconomic Considerations. *Clin Endocrinol (Oxf).* 2014; 81:71-6.
181. Moody GE, Beltran PJ, Mitchell P, Cajulis E, Chung YA, Hwang D, Kendall R, Radinsky R, Cohen P, Calzone FJ. IGF1R blockade with ganitumab results in systemic effects on the growth hormone-IGF axis in mice. *J Endocrinol.* 2014; 221:145-55.
182. Levine ME, Suarez JA, Brandhorst S, Balasubramanian P, Cheng CW, Madia F, Fontana L, Mirisola MG, Guevara-Aguirre J, Wan J, Passarino G, Kennedy BK, Wei M, Cohen P, Crimmins EM, Longo VD. Low Protein Intake Is Associated with a Major Reduction in IGF-1, Cancer, and Overall Mortality in the 65 and Younger but Not Older Population. *Cell Metabolism.* 2014; 19:407-17. PMID: PMC3988204
183. Milman S, Atzmon G, Huffman DM, Wan J, Crandall JP, Cohen P, Barzilai N. Low insulin-like growth factor-1 level predicts survival in humans with exceptional longevity. *Aging Cell.* 2014; 13:769-71. PMID: PMC4116456
184. Lee C, Wan J, Miyazaki B, Fang Y, Guevara-Aguirre J, Yen K, Longo V, Bartke A, Cohen P. IGF-1 Regulates the Age-Dependent Signaling Peptide humanin. *Aging Cell.* 2014; 13:958-61. PMID: PMC4172517
185. Jia Y, Ohanyan A, Lue YH, Swerdloff RS, Liu PY, Cohen P, Wang C. The effects of humanin and its analogues on male germ cell apoptosis induced by chemotherapeutic drugs. *Apoptosis.* 2015; 20:551-61.
186. Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. *Cell Metabolism.* 2015; 21, 443–454. PMID: PMC4350682

187. Lytvyn Y, Wan J, Lai V, Cohen P, Cherney DZ. The effect of sex on humanin levels in healthy adults and patients with uncomplicated type 1 diabetes mellitus. *Can J Physiol Pharmacol.* 2015; 93:239-4.
188. Brandhorst S, Choi IY, Wei M, Cheng CW, Sedrakyan S, Navarrete G, Dubeau L, Yap LP, Park R, Vinciguerra M, Di Biase S, Mirzaei H, Mirisola MG, Childress P, Ji L, Groshen S, Penna F, Odetti P, Perin L, Conti PS, Ikeno Y, Kennedy BK, Cohen P, Morgan TE, Dorff TB, Longo VD. A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan. *Cell Metabolism.* 2015; 22:86-99. PMID: PMC4509734
189. Paharkova P, Alvarez G, Nakamura H, Cohen P, Lee KW. Rat Humanin is encoded and translated in mitochondria and is localized to the mitochondrial compartment where it regulates ROS production. *Mol Cell Endocrinol.* 2015; 413:96-100. PMID: PMC3148406.
190. Lue Y, Swerdloff R, Wan J, Xiao J, French S, Atienza V, Canela V, Bruhn KW, Stone B, Jia Y, Cohen P, Wang C. The Potent Humanin Analogue (HNG) Protects Germ Cells and Leucocytes while Enhancing Chemotherapy-induced Suppression of Cancer Metastases in Male Mice. *Endocrinology.* 2015; 156:4511-21. PMID: PMC4655208
191. Allen DB, Backeljauw P, Bidlingmaier M, Biller B, Boguszewski M, Burman P, Butler G, Chihara K, Christiansen JS, Cianfarani S, Clayton PE, Clemmons D, Cohen P, Darendeliler F, Deal C, Dunger DP, Erfurth EM, Fuqua J, Grimberg A, Haymond M, Higham C, Ho KK, Hoffman AR, Hokken-Koelega AC, Johannsson G, Juul A, Kopchick JJ, Lee P, Pollak M, Radovick S, Robison L, Rosenfeld R, Ross RJ, Savendahl L, Saenger P, Toft Sorensen H, Stochholm K, Strasburger CJ, Swerdlow A, Thorner MO. Growth Hormone Safety Workshop Position Paper: a critical appraisal of recombinant human growth hormone therapy in children and adults. *Eur J Endocrinol.* 2015; 174:1-9.
192. Lee PD, Lustig RH, Lenders C, Baillargeon J, Wilson DM and the Glaser Pediatric Research Network Obesity Study Group. IGFBP-1 predicts insulin sensitivity and insulin area-under-the-curve in obese, nondiabetic adolescents. *Endocr Pract.* 2016 2:136-42.
193. Huffman DM, Farias Quipildor G, Mao K, Zhang X, Wan J, Apontes P, Cohen P, Barzilai N. Central insulin-like growth factor-1 (IGF-1) restores whole-body insulin action in a model of age-related insulin resistance and IGF-1 decline. *Aging Cell.* 2016; 15:181-6.
194. Sreekumar PG, Ishikawa K, Spee C, Mehta HH, Wan J, Yen K, Cohen P, Kannan R, Hinton DR. The Mitochondrial-Derived Peptide Humanin Protects RPE Cells from Oxidative Stress, Senescence, and Mitochondrial Dysfunction. *Invest Ophthalmol Vis Sci.* 2016; 57:1238-53.
195. Matsunaga D, Sreekumar PG, Ishikawa K, Terasaki H, Barron E, Cohen P, Kannan R, Hinton DR. Humanin Protects RPE Cells from Endoplasmic Reticulum Stress-Induced Apoptosis by Upregulation of Mitochondrial Glutathion. *PLoS One.* 2016; 11:e0165150
196. Christiansen JS, Backeljauw P, Bidlingmaier M, Biller B, Boguszewski M, Casanueva FF, Chanson P, Chatelain P, Choong CS, Clemmons DR, Cohen L, Cohen P, Frystyk J, Grimberg A, Hasegawa Y, Haymond M, Ho K, Hoffman AR, Holly JM, Horikawa R, Hoybye C, Jorgensen JO, Johannsson G, Juul A, Katznelson L, Kopchick JJ, Lee KO, Lee KW, Luo XP, Melmed S, Miller B, Misra M, Popović V, Rosenfeld RG, Ross J, Ross RJ, Saenger P, Strasburger CJ, Thorner MO, Werner H, Yuen KC. Growth Hormone Research Society Perspective on the Development of Long-Acting Growth Hormone Preparations. *Eur J Endocrinol.* 2016; 174:1-9.
197. Cobb LJ, Lee C, Xiao J, Yen K, Wong RG, Nakamura HK, Mehta HH, Gao Q, Ashur C, Huffman DM, Wan J, Muzumdar R, Barzilai N, Cohen P. Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. *Aging (Albany NY).* 2016; 8:796-809.

198. Dorff TB, Groshen S, Garcia A, Shah M, Tsao-Wei D, Pham H, Cheng CW, Brandhorst S, Cohen P, Wei M, Longo V, Quinn DI. Safety and feasibility of fasting in combination with platinum-based chemotherapy. *BMC Cancer*. 2016; 16:360.
199. Liang P, Henning SM, Schokrpur S, Wu L, Doan N, Said J, Grogan T, Elashoff D, Cohen P, Aronson WJ. Effect of dietary omega-3 fatty acids on tumor-associated macrophages and prostate cancer progression. *Prostate*. 2016; 76:1293-302.
200. Mitchell SJ, Madrigal-Matute J, Scheibye-Knudsen M, Fang E, Aon M, González-Reyes JA, Cortassa S, Kaushik S, Gonzalez-Freire M, Patel B, Wahl D, Ali A, Calvo-Rubio M, Burón MI, Guitierrez V, Ward TM, Palacios HH, Cai H, Frederick DW, Hine C, Broeskamp F, Habering L, Dawson J, Beasley TM, Wan J, Ikeno Y, Hubbard G, Becker KG, Zhang Y, Bohr VA, Longo DL, Navas P, Ferrucci L, Sinclair DA, Cohen P, Egan JM, Mitchell JR, Baur JA, Allison DB, Anson RM, Villalba JM, Madeo F, Cuervo AM, Pearson KJ, Ingram DK, Bernier M, de Cabo R. Effects of Sex, Strain, and Energy Intake on Hallmarks of Aging in Mice. *Cell Metabolism*. 2016; 23:1093-112.
201. Kim SJ, Guerrero N, Wassef G, Xiao J, Mehta HH, Cohen P, Yen K. The mitochondrial-derived peptide humanin activates the ERK1/2, AKT, and STAT3 signaling pathways and has age-dependent signaling differences in the hippocampus. *Oncotarget*. 2016; 7:46899-46912.
202. Matsunaga D, Sreekumar PG, Ishikawa K, Terasaki H, Barron E, Cohen P, Kannan R, Hinton DR. Humanin Protects RPE Cells from Endoplasmic Reticulum Stress-Induced Apoptosis by Upregulation of Mitochondrial Glutathion. *PLoS One*. 2016; 11:e0165150.
203. Perice L, Barzilai N, Verghese J, Weiss EF, Holtzer R, Cohen P, Milman S. Lower circulating insulin-like growth factor-I is associated with better cognition in females with exceptional longevity without compromise to muscle mass and function. *Aging (Albany NY)*. 2016; 8:2414-2424.
204. Lee AS, Brandhorst S, Rangel DF, Navarrete G, Cohen P, Longo VD, Chen J, Groshen S, Morgan TE, Dubeau L. Effects of Prolonged GRP78 Haploinsufficiency on Organ Homeostasis, Behavior, Cancer and Chemotoxic Resistance in Aged Mice. *Nature Scientific Reports*. 2017; 7:40919.
205. Wei M, Brandhorst S, Shelehchi M, Mirzaei H, Cheng CW, Budniak J, Groshen S, Mack WJ, Guen E, Di Biase S, Cohen P, Morgan TE, Dorff T, Hong K, Michalsen A, Laviano A, Longo VD. Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. *Science Translational Medicine*. 2017 Feb 15;9(377).
206. Cheng CW, Villani V, Buono R, Wei M, Kumar S, Yilmaz OH, Cohen P, Sneddon JB, Perin L, Longo VD. Fasting-Mimicking Diet Promotes Ngn3-Driven β -Cell Regeneration to Reverse Diabetes. *Cell*. 2017; 168:775-788.
207. Yu D, Du Z, Pian L, Li T, Wen X, Li W, Kim SJ, Xiao J, Cohen P, Cui J, Hoffman AR, Hu JF. Mitochondrial DNA Hypomethylation Is a Biomarker Associated with Induced Senescence in Human Fetal Heart Mesenchymal Stem Cells. *Stem Cells Int*. 2017:1764549. doi: 10.1155/2017/1764549. PMID: 28484495. PMID: 28484495.
208. Hine C, Kim HJ, Zhu Y, Harputlugil E, Longchamp A, Matos MS, Ramadoss P, Bauerle K, Brace L, Asara JM, Ozaki CK, Cheng SY, Singha S, Ahn KH, Kimmelman A, Fisher FM, Pissios P, Withers DJ, Selman C, Wang R, Yen K, Longo VD, Cohen P, Bartke A, Kopchick JJ, Miller R, Hollenberg AN, Mitchell JR. Hypothalamic-Pituitary Axis Regulates Hydrogen Sulfide Production. *Cell Metabolism*. 2017; 25:1320-1333.e5. doi: 10.1016/j.cmet.2017.05.003.

209. Ben-Avraham D, Govindaraju DR, Budagov T, Fradin D, Durda P, Liu B, Ott S, Gutman D, Sharvit L, Kaplan R, Bougnères P, Reiner A, Shuldiner AR, Cohen P, Barzilai N, Atzmon G. The GH receptor exon 3 deletion is a marker of male-specific exceptional longevity associated with increased GH sensitivity and taller stature. *Science Advances*. 2017; 3:e1602025.
210. Nashine S, Cohen P, Chwa M, Lu S, Nesburn AB, Kuppermann BD, Kenney MC. Humanin G (HNG) protects age-related macular degeneration (AMD) transmitochondrial ARPE-19 cybrids from mitochondrial and cellular damage. *Cell Death Dis*. 2017; 8:e2951.
211. Okada AK, Teranishi K, Lobo F, Isas JM, Xiao J, Yen K, Cohen P, Langen R. The Mitochondrial-Derived Peptides, HumaninS14G and Small Humanin-like Peptide 2, Exhibit Chaperone-like Activity. *Nature Scientific Reports*. 2017; 7:7802.
212. Kim SJ, Xiao J, Cohen P, Yen K. Subcellular Fractionation for ERK Activation Upon Mitochondrial-derived Peptide Treatment. *J Vis Exp* 2017; 127, e56496, doi:10.3791/56496.
213. Xiao J, Howard L, Wan J, Wiggins E, Vidal A, Cohen P, Freedland SJ. Low circulating levels of the mitochondrial-peptide hormone SHLP2: novel biomarker for prostate cancer risk. *Oncotarget*. 2017; 8:94900-94909.
214. Henning SM, Galet C, Gollapudi K, Byrd JB, Liang P, Li Z, Grogan T, Elashoff D, Magyar CE, Said J, Cohen P, Aronson WJ. Phase II prospective randomized trial of weight loss prior to radical prostatectomy. *Prostate Cancer Prostatic Dis*. 2018; 21:212-220.
215. Qin Q, Delrio S, Wan J, Widmer RJ, Cohen P, Lerman LO, Lerman L. Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction. *Int J Cardiol*. 2018 Mar 1;254:23-27. doi: 10.1016/j.ijcard.2017.12.001. PMID: 29242099.
216. Kim SJ, Mehta HH, Wan J, Kuehnemann C, Chen J, Hu JF, Hoffman AR, Cohen P. Mitochondrial peptides modulate mitochondrial function during cellular senescence. *Aging (Albany NY)*. 2018; 10:1239-1256.
217. Mao K, Quipildor GF, Tabrizian T, Novaj A, Guan F, Walters RO, Delahaye F, Hubbard GB, Ikeno Y, Ejima K, Li P, Allison DB, Salimi-Moosavi H, Beltran PJ, Cohen P, Barzilai N, Huffman DM. Late-life targeting of the IGF-1 receptor improves healthspan and lifespan in female mice. *Nature Communications*. 2018; 9:2394.
218. Qin Q, Mehta H, Yen K, Navarrete G, Brandhorst S, Wan J, Delrio S, Lerman LO, Cohen P, Lerman A. Chronic Treatment With the Mitochondrial Peptide Humanin Prevents Age-related Myocardial Fibrosis in mice. *Am J Physiol Heart Circ Physiol*. 2018; 315:H1127-H1136.
219. Yen K, Wan J, Mehta HH, Miller B, Christensen A, Levine ME, Salomon MP, Brandhorst S, Xiao J, Kim SJ, Navarrete G, Campo D, Harry GJ, Longo V, Pike CJ, Mack WJ, Hodis HN, Crimmins EM, Cohen P. Humanin Prevents Age-Related Cognitive Decline in Mice and is Associated with Improved Cognitive Age in Humans. *Nature Scientific Reports*. 2018; 8:14212. doi: 10.1038/s41598-018-32616-7.
220. Nashine S, Cohen P, Nesburn AB, Kuppermann BD, Kenney MC. Characterizing the protective effects of SHLP2, a mitochondrial-derived peptide, in macular degeneration. *Nature Scientific Reports*. 2018; 8:15175. doi: 10.1038/s41598-018-33290-5.
221. Liang P, Henning SM, Guan J, Grogan T, Elashoff D, Olefsky JM, Cohen P, Aronson WJ. Role of Host GPR120 in Mediating Dietary Omega-3 Fatty Acid Inhibition of Prostate Cancer, *JNCI: Journal of the National Cancer Institute*. 2019; 111:52-59.

222. Zaman F, Zhao Y, Calvin B, Mehta HH, Wan J, Chrysis D, Ohlsson C, Fadeel B, Cohen P, Säwendahl L. Humanin is a novel regulator of Hedgehog signaling and prevents glucocorticoid-induced bone growth impairment. *FASEB J*. 2019; 33:4962-4974.
223. Kim SJ, Chun M, Lee C, Cohen P. GRSF1 is an age-related regulator of senescence. *Nature Scientific Reports*. 2019. Apr 3; 9(1): 5546. doi: 10.1038/s41598-019-42064-6.
224. Miller B, Arpawong TE, Jiao H, Kim SJ, Yen K, Mehta HM, Wan J, Carpten JC, Cohen P. Comparing Nuclear and Mitochondrial DNA from a Multi-Ethnic Cohort to Adjust for Genetic Ancestry in Association Studies. *Cells*. 2019. 8(4), 306; doi: 10.3390/cells8040306
225. Breton CV, Song AY, Xiao J, Kim SJ, Mehta HH, Wan J, Yen K, Sioutas C, Lurmann F, Xue S, Morgan TE, Zhang J, Cohen P. Effects of air pollution on mitochondrial function, mitochondrial DNA methylation, and mitochondrial peptide expression. *Mitochondrion*. 2019; 46:22-29.
226. Mehta HH, Xiao J, Ramirez R, Miller B, Kim SJ, Cohen P, Yen K. Metabolomic profile of diet-induced obesity mice in response to humanin and small humanin-like peptide 2 treatment. *Metabolomics*. 2019; 15:88.
227. Kim SJ, Miller B, Mehta HH, Xiao J, Wan J, Arpawong TE, Yen K, Cohen P. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. *Physiol Rep*. 2019; 7:e14171.
228. Collett-Solberg PF, Ambler G, Backeljauw PF, Bidlingmaier M, Biller BMK, Boguszewski MCS, Cheung PT, Choong CSY, Cohen LE, Cohen P, Dauber A, Deal CL, Gong C, Hasegawa Y, Hoffman AR, Hofman PL, Horikawa R, Jorge AAL, Juul A, Kamenický P, Khadilkar V, Kopchick JJ, Kriström B, Lopes MLA, Luo X, Miller BS, Misra M, Netchine I, Radovick S, Ranke MB, Rogol AD, Rosenfeld RG, Saenger P, Wit JM, Woelfle J. Diagnosis, Genetics, and Therapy of Short Stature in Children: A Growth Hormone Research Society International Perspective. *Horm Res Paediatr*. 2019; 92:1-14. PMID: 31514194
229. Liang P, Henning SM, Guan J, Grogan T, Elashoff D, Cohen P, Aronson WJ. Effect of dietary omega-3 fatty acids on castrate-resistant prostate cancer and tumor-associated macrophages. *Prostate Cancer Prostatic Dis*. 23:127-135; 2020. PMID: 31439889
230. D'Souza RF, Woodhead JST, Hedges CP, Zeng N, Wan J, Kumagai H, Lee C, Cohen P, Cameron-Smith D, Mitchell CJ, Merry TL. Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition. *Aging (Albany NY)*. 2020 Mar 17;12. doi: 10.18632/aging.102944. Online ahead of print. PMID: 32182209.
231. Woodhead JST, D'Souza RF, Hedges CP, Wan J, Berridge MV, Cameron-Smith D, Cohen P, Hickey AJR, Mitchell CJ, Merry TL. High-intensity interval exercise increases humanin, a mitochondrial encoded peptide, in the plasma and muscle of men. *J Appl Physiol*. 2020 Apr 9. doi: 10.1152/jappphysiol.00032.2020. Online ahead of print. PMID: 32271093

Editorials and Reviews

1. Neely EK, Beukers WM, Oh Y, Cohen P, Rosenfeld RG: Insulin-like growth factor receptors. *Acta Paediatr Scand* [Suppl] 372:116-21, 1991.
2. Cohen P, Fielder PJ, Hasegawa Y, Frisch H, Giudice LC, Rosenfeld RG: Clinical aspects of insulin-like growth factor binding proteins. *Acta Endocrinol* [Copenh] 124[Suppl 2]:74-85, 1991.
3. Fielder PJ, Guevara-Aguirre J, Rosenbloom AL, Cohen P, Hintz RL, Rosenfeld RG: Regulation of serum insulin-like growth factors (IGFs) and their binding proteins (IGFBPs) in Ecuadorian growth hormone receptor deficient patients. *Acta Paediatr Scand* [Suppl] 377:104-109, 1991.
4. Cohen P, Ocrant I, Fielder PJ, Neely EK, Lamson G, Oh Y, Deal LC, Pham H, Gargosky SE, Giudice Rosenfeld RG: Insulin-like growth factors: Implications for aging. *Psyconeuroendocrinology*, 1992.
5. Lamson G, Giudice LC, Cohen P, Fielder PJ, Oh Y, Hintz RL, Rosenfeld RG: Proteolysis of insulin-like growth factor binding protein-3 may be a common regulatory mechanism of IGF action in vivo. *Growth Regulation*, 3:91-95, 1993.
6. Rosenbloom AL, Guevara-Aguirre J, Fielder PJ, Gargosky SE, Cohen P, Rosenfeld RG. Insulin-like growth factor binding proteins -2 and -3 in Ecuadorian patients with growth hormone receptor deficiency and their parents. In: Lessons from Laron Syndrome, *Pediatric and Adolescent Endocrinology*, Basel, Karger Vol 24, p 185-191, 1993.
7. Cohen P, Lamson G, Okajima T, Rosenfeld RG: Transfection of the human IGFBP genes into Balb/c fibroblasts: a model for the cellular functions of IGFBPs. *Growth Regulation*, 3:23-26, 1993.
8. Rosenfeld RG, H. Pham, Cohen P et. al.: Physiology of the Insulin-like growth factor binding proteins. *Acta. Paediatrica* (Suppl). 399:154-8, 1994.
9. Cohen P, Peehl DM, Rosenfeld RG: The insulin-like growth factor axis in the Prostate. *Horm Metab Res*, 26:81-4; 1994.
10. Cohen P, Rosenfeld RG: Physiological and Clinical Relevance of the IGFBPs. *Current Opinions in Pediatrics*. 1994. 6:462-467.
11. Katz LEL, Rosenfeld RG, Cohen P: Clinical Significance of IGFBPs. *The Endocrinologist*. 5: 41-8; 1995.
12. Peehl DM, Cohen P, Rosenfeld RG: The IGF system in the prostate. *World Journal of Urology*. 13:306-311, 1995.
13. Rajah R, Katz L, Nunn S, Solberg P, Beers T, and Cohen P. IGFBP proteases - functional regulators of cell growth. *Progress in Growth Factors Research*, 6:273-284, 1996.
14. Peehl DM, Cohen P, Rosenfeld RG: The role of insulin-like growth factors in prostate biology. *J. Andrology*, 17:2-4, 1996.
15. Solberg P, Cohen P: The role of the insulin-like growth factor binding proteins and their proteases in modulating IGF action. In: *Endocrinology and Metabolism Clinics of North America*, 25:591-614, 1996.
16. Nunn SE, Beers-Gibson T, Cohen P. Regulation of prostate cell growth by the IGFBPs and their proteases. *Endocrine* 7:115-118;1997.
17. Grimberg A, Cohen P: Optimizing Growth Hormone therapy in children. *Hormone Research* 1997; 58 (Suppl 5):11-15.

18. Cohen P, Peehl DM, Rosenfeld R. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. *Br J Cancer*. 1998; 78:554-556.
19. Cohen P. Implications of IGF-I elevations in prostate cancer sera. *Journal of the National Cancer Institute*. 1998 Jun 17;90(12):876-879.
20. Ferry RJ Jr, Katz LE, Grimberg A, Cohen P, Weinzimer SA. Cellular actions of insulin-like growth factor binding proteins. *Horm Metab Res* 1999; 31:192-202.
21. Grimberg A, Cohen P: Growth hormone and prostate cancer: Guilty by association? 22:64-73, 1999 *J Endocrinol Invest*.
22. Ferry Jr RJ, Cohen P. The Insulin-Like Growth Factor Axis in Pediatrics. *Clin Pediatr Endocrinol*. 1999; 8:1-10.
23. Wetterau LA, Moore MG, Lee KW, Shim ML, Cohen P. Novel Aspects of the Insulin-like Growth Factor Binding Proteins. *Mol Genet Metab* 1999; 68:161-181.
24. Shim M, Cohen P. IGFs and human cancer: implications regarding the risk of growth hormone therapy. *Horm Res* 1999;51 Suppl 3:42-51
25. Grimberg A, Cohen P: Role of insulin-like growth factors in growth control and carcinogenesis. *J Cell Physiol* 2000; 183:1-9.
26. Pollak M, Besser GM, Cohen P Rosenfeld RG. Growth Hormone, IGFs and Neoplasia – An Overview. *Growth Hormone and IGF Research* 10:S1-3; 2000
27. Collett-Solberg PF, Cohen P. Genetics, chemistry, and function of the IGF/IGFBP system. *Endocrine* 2000; 12:121-36.
28. Wetterau L, Cohen P. New Paradigms for GH Therapy in Children. *Horm Res* 2000; 53: S3 31-36.
29. Clayton PE, Cohen P, Tanaka T, Hintz RL, Laron Z, Sizonenko PC. Diagnosis of Growth Hormone Deficiency in Childhood. *Horm Res* 2000; 53: Suppl S3 30.
30. Cohen P, DR Clemmons RG Rosenfeld. Does the GH –IGF axis play a role in cancer pathogenesis? *Growth Hormone & IGF Research* 2000, 10:1–9.
31. Wetterau L, Cohen P. Role of insulin-like growth factor monitoring in optimizing growth hormone therapy. *J Pediatr Endocrinol Metab* 2000;13 Suppl 6:1371-6.
32. Cohen P, Franklin S, Rogol A, Bright G, Rosenfeld RG, on behalf of the North American Norditropin Study Group. What is the optimal dose of growth hormone? *Medical Forum Highlights*. 2000; 1:4-5.
33. Sizonenko PC, Clayton PE, Cohen P, Hintz RL, Tanaka T, Laron Z. Diagnosis and management of growth hormone deficiency in childhood and adolescence. Part 1: Diagnosis of growth hormone deficiency. *Growth Hormone and IGF Research*, 11: 137-165, 2001.
34. Lee K, Cohen P. Individualizing Growth Hormone Dosing in Children. *Horm Res* 2001; 56 (Suppl 1): 29–34.
35. Cohen P. Clinical implications of the IGF-cancer connection. *Growth Horm IGF Res* 2001; 11:336-8.
36. H Simpson, R Savine, P Sonksen BA Bengtsson, L Carlsson, JS Christiansen, D Clemmons, P Cohen. R Hintz, K Ho, P Mullis, I Robinson, C Strasburger, T Tanaka, M Thorner. Growth hormone replacement therapy for adults: Into the new millennium. *Growth Hormone & IGF Research* 2002, 12, 1–33.

37. Tanaka T, Cohen P, Clayton P, Laron Z, Hintz R, Sizonenko P. Diagnosis and management of growth hormone deficiency in childhood and adolescence - Part 2: Growth hormone treatment in growth hormone deficient children. *Growth Horm IGF Res* 2002; 12:323-9.
38. Lee KW, Cohen P. Nuclear effects: unexpected intracellular actions of insulin-like growth factor binding protein-3. *J Endocrinol* 2002; 175:33-40.
39. Monzavi R, Cohen P. IGFs and IGFbps: role in health and disease. *Best Pract Res Clin Endocrinol Metab*. 2002; 16:433-47.
40. Lee K-W, Cohen P. Individualized Growth Hormone Therapy in Children: Advances Beyond Weight-based Dosing. 2003 *J Ped Endo Metab* 16:625-630.
41. Ali O, Cohen P. Insulin-like growth factors and their binding proteins in children born small for gestational age: implication for growth hormone therapy. *Horm Res*. 2003; 60:S115-23.
42. Ali O, Cohen P, Lee KW. Epidemiology and Biology of Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) as an Anti-Cancer Molecule. *Horm Metab Res*. 2003; 35:726-33.
43. Denny CT, Cohen P. Pancreatic Beta Cells - The Sweet Life. *Pediatr Res*. 2004; 55:361-2.
44. Cohen P, Dunger DB. Hot topics. *Growth Horm IGF Res*. 2004; 14:S34.
45. Park P, Cohen P. The role of insulin-like growth factor I monitoring in growth hormone-treated children. *Horm Res*. 2004; 62: S59-65.
46. Randhawa R, Cohen P. The role of the insulin-like growth factor system in prenatal growth. *Mol Genet Metab* 2005; 86:84-90.
47. Yang J, Anzo M, Cohen P. Control of aging and longevity by IGF-I signaling. *Exp Gerontol*. 2005; 40:867-72.
48. Cohen P. Overview of the IGF-I system. *Horm Res* 2006; 65 Suppl 1:3-8.
49. Cohen P. Insulin-Like Growth Factor Binding Protein-3: Insulin-Like Growth Factor Independence Comes of Age. *Endocrinology*. 2006; 147:2109-2111.
50. Pawlikowska-Haddad A, Cohen P. Advances in pediatric growth hormone therapy: IGF-I-based dosing. *Indian Pediatr*. 2006; 43:577-81.
51. Cohen P. Controversy in Clinical Endocrinology: Problems with Reclassification of IGF-1 Production and Action Disorders. *J Clin Endocrinol Metab*. 2006; 91:4235-6.
52. Rosenthal S, Cohen P, Clayton P, Backeljauw P, Bang P, Ten S. Treatment perspectives in idiopathic short stature with a focus on IGF-I deficiency. *Pediatr Endocrinol Rev*. 2007 May;4 Suppl 2:252-71.
53. Kaplan SA, Cohen P. The Somatomedin Hypothesis 2007: Fifty Years Later. *J Clin Endocrinol Metab*. 2007; 92:4529-35.
54. Wit JM, Clayton PE, Rogol AD, Savage MO, Saenger PH, Cohen P. Idiopathic short stature: Definition, epidemiology, and diagnostic evaluation. *Growth Horm IGF Res*. 2008; 18:89-110.
55. Wit JM, Reiter EO, Ross JL, Saenger PH, Savage MO, Rogol AD, Cohen P. Idiopathic short stature: Management and growth hormone treatment. *Growth Horm IGF Res*. 2008; 18:111-35.
56. Cohen P. Serum insulin-like growth factor I (IGF-I) level should be part of the evaluation of children with short stature. *Pediatr Endocrinol Rev*. 2008; 5 Suppl 3:834-6.
57. Salusky IB, Cohen P. Lost in translation? *Pediatr Res*. 2008; 64:225.

58. Hernandez MI, Cohen P. Surprising New Height Regulating Genes: Beyond Growth Hormone and IGF-I. *Pediatr Res.* 2008; 64:461.
59. Cohen P. Growth hormone treatment: evidence, practice, and emerging issues. *Manag Care.* 2009; 18(8 Suppl 6):2-3.
60. Keni J, Cohen P. Optimizing growth hormone dosing in children with idiopathic short stature. *Horm Res.* 2009; 71 Suppl 1:70-4.
61. Cohen P. Clinical management of growth hormone therapy for children. *Manag Care.* 2009; 18(8 Suppl 6):4-9.
62. Savage MO, Cohen L, Cohen AJ, Cohen P, Saenger PH. Pathophysiology, assessment and management of the child with growth hormone resistance. *Pediatr Endocrinol Rev.* 2010; 7:347-56.
63. Pawlikowska-Haddal A, Cohen P, Cook DM. How useful are serum IGF-I measurements for managing GH replacement therapy in adults and children? *Pituitary.* 2012; 15:126-34.
64. Yen K, Lee C, Mehta HH, Cohen P. The Emerging Role of the Mitochondrial-Derived Peptide Humanin in Stress Resistance. *J Mol Endocrinol.* 2013; 50:R11-9. PMID: PMC3705736
65. Lee C, Yen K, Cohen P. Humanin: a harbinger of mitochondrial-derived peptides? *Trends Endocrinol Metab.* 2013; 24:222-8. PMID: PMC3641182
66. Cohen P. New Role for the Mitochondrial Peptide Humanin: Protective Agent Against Chemotherapy-Induced Side Effects. *J Natl Cancer Inst.* 2014; 106:dju006. PMID: PMC3982780
67. Høybye C, Cohen P, Hoffman AR, Ross R, Biller BM, Christiansen JS; Growth Hormone Research Society. Status of long-acting-growth hormone preparations - 2015. *Growth Horm IGF Res.* 2015; 25:201-6.
68. Xiao J, Kim SJ, Cohen P, Yen K. Humanin: Functional Interfaces with IGF-I. *Growth Horm IGF Res.* 2016; 29:21-27.
69. Lee C, Kim KH, Cohen P. MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. *Free Radic Biol Med.* 2016; 100:182-187.
70. Kim SJ, Wan J, Cohen P, Yen K. Mitochondrial derived peptides as novel regulators of metabolism. *J Physiol.* 2017 595:6613-6621.
71. Saenger P, Cohen P. Feeling misguided: a comment on the US guidelines on growth hormone and insulin-like growth factor-I treatment in children and adolescents. *Curr Opin Pediatr.* 2017; 29:472-474.
72. Davies JMS, Cillard J, Friguet B, Cadenas E, Cadet J, Cayce R, Fishmann A, Liao D, Bulteau AL, Derbré F, Rébillard A, Burstein S, Hirsch E, Kloner RA, Jakowec M, Petzinger G, Sauce D, Sennlaub F, Limon I, Ursini F, Maiorino M, Economides C, Pike CJ, Cohen P, Salvayre AN, Halliday MR, Lundquist AJ, Jakowec NA, Mehta-Grigoriou F, Mericskay M, Mariani J, Li Z, Huang D, Grant E, Forman HJ, Finch CE, Sun PY, Pomatto LCD, Agbulut O, Warburton D, Neri C, Rouis M, Cillard P, Capeau J, Rosenbaum J, Davies KJA. The Oxygen Paradox, the French Paradox, and age-related diseases. *Geroscience.* 2017; 39:499-550. PMID: 29270905.
73. Xiao J, Cohen P, Stern MC, Odedina F, Carpten J, Reams R. Mitochondrial biology and prostate cancer ethnic disparity. *Carcinogenesis.* 2018; doi.org/10.1093/carcin/bgy133.
74. Collett-Solberg PF, Jorge AAL, Boguszewski MCS, Miller BS, Choong CS, Cohen P, Hoffman AR, Luo X, Radovick S, Saenger P. Growth hormone therapy in children; research and practice – A review. *Growth Horm IGF Res.* 2019; 44:20-32.

75. Kim SJ, Miller B, Kumagai H, Yen K, Cohen P. MOTS-c: an equal opportunity insulin sensitizer. *Journal of Molecular Medicine*, 2019; 97: 487-490.
76. Miller B, Kim SJ, Kumagai H, Mehta HH, Xiang W, Liu J, Yen K, Cohen P. Peptides derived from small mitochondrial open reading frames: Genomic, biological, and therapeutic implications. *Exp Cell Res*. 2020 May 5:112056. doi: 10.1016/j.yexcr.2020.112056. [Epub ahead of print] PMID: 32387288

Chapters in Textbooks and Proceedings

78. Cohen P, Rosenfeld RG: Growth problems in adolescence. In: *Textbook of Adolescent Medicine*, Editors: MacAnarney, Kreipe, Orr, and Comerci. p.p. 494-508. WB Saunders, Philadelphia, 1992.
79. Rosenfeld RG, Rosenbloom AL, Guevara-Aguirre J, Berg MA, Cohen P, et al.: Laron-type dwarfism in Ecuador. In: *Proceedings of the 9th International Congress of Endocrinology*, 1993, p 85-9.
80. Cohen P, Fielder PJ, Guevara-Aguirre J, Diamond FB, Wilson K, Berg MA, Francke U, Gargosky SE, Vaccarello MA, Rosenbloom AL, Rosenfeld RG. Medical and scientific aspects of growth hormone receptor deficiency (Laron syndrome) in Ecuador. In: *Growth hormone II: basic and scientific aspects*, Editor: B. Bercu. Serono Symposia, page 279-285, 1994.
81. Cohen P, Peehl DM, Bhala A, Dong G, Hintz RL, Rosenfeld RG: The IGF axis in prostatic disease. In: *The IGFs and their regulatory proteins*. R.C. Baxter, P.D. Gluckman, R.G. Rosenfeld, editors. Elsevier Science B.V. Amsterdam. p.p. 369-77. 1994.
82. Cohen P, Rosenfeld RG: The insulin-like growth factor axis. In: *Human Growth Hormone, Basic and Scientific Aspects*, Editor: Rosenbloom AL, Shiverick J. CRC Press, Boca Raton, Florida, pp: 43-58. 1995.
83. Cohen P, Rosenfeld RG: Growth regulation. In: *Textbook of Endocrine Physiology*, Editors: Griffin and Ojeda. Oxford University Press pages 244-259; 1996.
84. Katz LEL, Cohen P: Growth factors in the fetus. *Textbook of neonatal physiology*. WB Saunders, Philadelphia, pp 268-279, Editor, Pollin R, 1997.
85. Grimberg A, Rajah R, Zhao H, Cohen P: The prostatic IGF system: new levels of complexity. In: *Molecular mechanisms to regulate the Activities of Insulin-like Growth factors*, Takano, Hizuka, and Takahashi, eds. pp 205-215, 1998.
86. Weinzimer S, Cohen P: The IGF axis in the male reproductive system. In: *The IGFs*, Rosenfeld and Roberts, ed, 1999 p.p. 172-184.
87. Collett-Solberg PF, Rajah R, Weinzimer SA, Cohen P. The impact of IGFbps and IGFbp proteases on tissue growth. In: Johnston FE, Eveleth PB, Zemel B (ed). *Human Growth in Context*. London: Smith-Gordon, 1999.
88. Cohen P: Hyperpituitarism, Tall Stature, and Overgrowth Syndromes. In: *Nelson Textbook of Pediatrics*, 16th edition, Behrman, Kliegman, Jenson, Barlow, eds. W. B. Saunders, 1999.
89. Cohen P, Rosenfeld RG: Growth regulation. In: *Textbook of Endocrine Physiology*, 2nd edition, Editors: Griffin and Ojeda. Oxford University Press; 2001.
90. Cohen P, Rosenfeld RG: Growth Disorders. In: *Textbook of Pediatric Endocrinology*, 2nd edition, Editor: Sperling M. 2002.
91. Weinzimer S, Cohen P. Biological significance of the IGFbps. *Growth and Lactogenic Hormones*. R Rappaport Ed. Elsevier Science B.V. 2002.
92. Cohen P, Ballard P: Mechanisms of Hormone Action. In: *Rudolph Textbook of Pediatrics*, 4th edition, 2003.
93. Cohen P: Hyperpituitarism, Tall Stature, and Overgrowth Syndromes. In: *Nelson Textbook of Pediatrics*, 17th edition, Behrman, Kliegman, Jenson, Barlow, Eds. W. B. Saunders, 2003.
94. De Leon D, Cohen P, Katz LEL: Growth factors and the regulation of fetal growth. *Textbook of neonatal physiology*. WB Saunders, Philadelphia, pp 1880-1890, Editors, Polin, Fox, Abman, 2004.

95. Cohen P, Rosenfeld RG: Growth regulation. In: *Textbook of Endocrine Physiology*, 3rd edition, Editors: Griffin and Ojeda. Oxford University Press; 2004.
96. Heber D and Cohen P. Endocrine and paracrine factors in carcinogenesis. In *Nutritional Oncology*. 2nd Edition. Editors: Heber, Blackburn, Go and Milner. Academic Press 2006.
97. Cohen P: Hyperpituitarism, Tall Stature, and Overgrowth Syndromes. In: *Nelson Textbook of Pediatrics*, 18th edition, Behrman, Kliegman, Jenson, Barlow, Eds. W. B. Saunders, 2007.
98. Cohen P, Rosenfeld RG: Growth Disorders. In: *Textbook of Pediatric Endocrinology*, 3rd edition, Editor: Sperling M. 2008.
99. Ali O, Cohen P. The Pituitary Gland and Growth Failure. In: *Manual of Endocrinology* 4th edition, Lippincott, Wilkins, Williams Editor: Lavin N. 2009.
100. Barzilai N, Huffman DM, Cohen P, Muzumdar RH. The Role of the IGF-1 and its Partners in Central and Peripheral Metabolism: Considerations for Extending Healthy Life Span. IN: *IGFs: Local Repair and Survival Factors Throughout Life Span. Research and Perspectives in Endocrine Interactions* 2010, p. p. 143-153.
101. Hosono E, Cohen P: Hyperpituitarism, Tall Stature, and Overgrowth Syndromes. In: *Nelson Textbook of Pediatrics*, 19th edition, Behrman, Kliegman, Jenson, Barlow, Eds. W. B. Saunders, 2011.
102. Chin YP, Cohen P: Idiopathic Short Stature. In: *Pediatric Endocrinology: A Practical Clinical Guide*, 2nd edition, Radovick, S; MacGillivray, MH. (Eds.) Springer, 2013.
103. Cohen P. Personalized Aging. In: *The Upside of Aging*. Editor: Paul Irving. Wiley. 2014.
104. Backeljauw PF, Dattani MT, Cohen P, Rosenfeld RG: Disorders of Growth Hormone and IGF Secretion and Action. In: *Pediatric Endocrinology*, 4th edition, Editor: Sperling M. 2014.
105. Cohen P. Personalized Aging. In: *The Future of Aging*. Editor: Paul Irving. Milken Institute Press. 2016.

Editor for Books and Proceedings:

106. Ritzin M, Lippe B, Czernichow P, Cohen P (eds). Proceedings of the 28th International Workshop on Growth Hormone. *Horm Res* 2000; 53:S3.
107. Pollak M, Besser GM, Cohen P Rosenfeld RG (eds). Proceedings of the First International Workshop on Growth Hormone, IGFs and Neoplasia. *Growth Hormone and IGF Research* 10: Supplement A; 2000.
108. Cohen P (guest editor). *Medical Forum Highlights*. GH Treatment of ISS. 2008.
109. Cohen P (editor). Growth hormone treatment: evidence, practice, and emerging issues. *Manag Care*. 2009; 18(8 Suppl 6):2-18.

Internet publications, presentations, and interviews:

110. Rosenfeld RG, Sperling MA, Cohen P, Allen DB, Nelly Maura N. Growth and Growth Hormone: Current Applications and Clinical Updates. 2008. <http://www.healio.com/endocrinology/pediatric-endocrinology/news/online/%7Ba7a6855e-f38e-4c0c-a1d5-dbd7cdf4ce4c%7D/growth-and-growth-hormone-current-applications-and-clinical-updates#3>
111. Cohen P. AN AGING ODYSSEY: ETERNAL YET CURRENT. 2012. http://gero.usc.edu/files/Cohen_Installation_Speech.pdf
112. Cohen P. Mitochondrial-Derived Peptides and Their Roles in Aging. UTHSCSA Barshop Institute. 2013. <https://www.youtube.com/watch?v=jTptlsn4XPc>
113. Cohen P. Growth-hormone dose optimization. 2015. <https://vimeo.com/130868170>
114. Cohen P. The complex relationship between the GH/IGF axis and ageing and longevity. ESPE 2015. <https://www.youtube.com/watch?v=sz1NxZokFpE>
115. Cohen P. Mitochondrial-Derived Peptides and their Roles in Aging and Related Diseases. Rejuvenation Biotechnology Conference. 2016. <https://www.youtube.com/watch?v=bfCCtUN1kws>
116. Cohen P. Personalized Aging: Extending Lifespans and Healthspans. Next-Avenue. 2016. <http://www.nextavenue.org/personalized-aging-extending-lifespans-healthspans/>
117. Exploring the biological effects of mitochondrial peptides (an Interview with Dean Pinchas Cohen accompanying the NIEHS Keystone lecture). By Douglas Ganini da Silva. Environmental factor (NIEHS News) April 2017. <https://www.niehs.nih.gov/news/newsletter/2017/4/science-highlights/peptides/index.htm>
118. Will You Live to a Healthy 100? A 2017 Milken Global Conference Panel with Francis Collins, Director, National Institutes of Health, Pinchas Cohen, Dean, USC Davis School of Gerontology, Elizabeth Blackburn, President, Salk Institute, Nir Barzilai, Director, Einstein Institute of Aging, and Joon Yun, President, Palo Alto Investors. <https://www.youtube.com/watch?v=IJOlcgDeCg8>
119. Cohen P. How Universities Drive Innovation in Aging. Forbes Magazine Personal Finance. 2018. <https://www.forbes.com/sites/nextavenue/2018/03/09/how-universities-drive-innovation-in-aging/#1ed298f37f03>
120. Pinchas Cohen. COVID-19: The Importance of Geroscience in Promising Research Directions. Milken Institute - Power of Ideas. Published April 29, 2020. <https://milkeninstitute.org/power-of-ideas/covid-19-importance-geroscience-promising-research-directions>.